Epigenetic regulation of inflammation in stroke

Gavin Yong-Quan Ng, Lim Yun-An, Christopher G. Sobey, Thameem Dheen, David Yang-Wei Fann and Thiruma V. Arumugam

Abstract: Despite extensive research, treatments for clinical stroke are still limited only to the administration of tissue plasminogen activator and the recent introduction of mechanical thrombectomy, which can be used in only a limited proportion of patients due to time constraints. A plethora of inflammatory events occur during stroke, arising in part due to the body’s immune response to brain injury. Neuroinflammation contributes significantly to neuronal cell death and the development of functional impairment and death in stroke patients. Therefore, elucidating the molecular and cellular mechanisms underlying inflammatory damage following stroke injury will be essential for the development of useful therapies. Research findings increasingly point to the likelihood that epigenetic mechanisms play a role in the pathophysiology of stroke. Epigenetics involves the differential regulation of gene expression, including those involved in brain inflammation and remodelling after stroke. Hence, it is conceivable that epigenetic mechanisms may contribute to differential interindividual vulnerability and injury responses to cerebral ischaemia. In this review, we summarize recent findings on the emerging role of epigenetics in the regulation of neuroinflammation in stroke. We also discuss potential epigenetic targets that may be assessed for the development of stroke therapies.

Keywords: cytokines, epigenetics, inflammasome, ischaemic stroke, neuroinflammation

Received: 4 March 2018; revised manuscript accepted: 29 March 2018.
Briefly, the inflammatory cascade is initiated via the molecular release of cytokines and chemokines by inflammatory cells within the ischaemic territory, which leads to the activation of endothelial cells to upregulate numerous inflammatory mediators that facilitate leukocyte infiltration into the brain parenchymal region. Infiltrated leukocytes produce and release cytotoxic and proinflammatory chemicals that induce toxicity to neurons and glial cells. In addition, activation of the inflamma-
some complex in various brain cells leads to the production of proinflammatory cytokines such as IL-1β and IL-18. Similarly, the complement cascade is activated in neuronal and glial cells. Collectively, these mechanisms lead to structural and functional impairment of neuronal cells in the ischaemic area.

Many factors have been identified that affect stroke risk and functional outcome. Risk factors for stroke are numerous, and include lifestyle factors such as obesity, diabetes, smoking, advanced age and lack of physical activity. Thus, as the pathogenesis of stroke is known to be impacted by such environmental/external factors, there opens up a wider area of interest as to whether stroke incidence and outcome might also be influenced by epigenetics.

Gene expression can be modulated via changes in the DNA sequence itself, which may even be heritable if changes occur in DNA sequences affecting germ cells. Epigenetics refers to the interaction of environmental factors with the genome that may also result in heritable and modifiable gene expression or phenotype, which does not confer any changes in the DNA sequence itself. The eukaryotic genome is tightly regulated in terms of its organization and differential control mechanisms from the DNA sequence to the post-translational level. At every level of eukaryotic control, such regulatory processes are being controlled by another layer of epigenetic regulation. As such, exposure to various environmental stimuli may alter the epigenome status, which in turn differentially controls the modulation of gene expression and protein activity. As such, higher-order DNA activity is modulated by a dynamic interaction between genes and environmental factors. Epigenetic processes thus serve as an important spatial and temporal regulator of a number of biological processes in the body, such as homeostasis, development and ageing.

Recently, much attention has been shifted towards the study of epigenetics in influencing the risks and manifestation of various diseases, such as cancer. Epigenetic markers represent a useful and reliable prognostic risk biomarker and can be used to explain individual susceptibility towards the pathogenesis of diseases. However, stroke is not manifested as a monogenic disease, but represents a complicated polygenic disease that especially affects the ageing population, and is often confounded by many lifestyle-related metabolic disorders. As individuals are subjected to a myriad of environmental factors throughout life, it is possible that stroke incidence and outcome may be differentially regulated by epigenetic mechanisms between individuals. This may help to explain why outcomes from studies conducted on rodent models may be poorly translated into human stroke patients as their epigenomes will differ greatly. Until recently, epigenetic studies in stroke have been in their infancy, and relevant information is only just beginning to emerge.

While conventional therapeutic approaches that aimed to intervene against ischaemic stroke damage have been unsuccessful, new approaches have started to shift attention towards the area of regenerative medicine. Regenerative therapeutic approaches now aim to attenuate inflammatory-induced damage, to promote neuroprotection and neural repair, prevent ischaemic-induced cell death, as well as maintain structural and functional homeostasis by promoting cerebral remodelling and regeneration. These regenerative processes seem to be tightly regulated via epigenetic mechanisms, and depending on the state of the epigenome of the individual, the degree of regeneration may differ and so the extent of damage incurred will vary. As such, it is paramount that studies consider the complex and interrelated genetic and molecular interactions from an epigenetic viewpoint. This review mainly focuses on how epigenetic mechanisms might contribute to post-ischaemic neuroinflammation and neuronal cell death. The next section will describe mechanisms of epigenetics and epigenetic regulation of the inflammatory process that contributes to infarct development following ischaemic stroke.

Epigenetic mechanisms
The eukaryotic genome has a distinct organizational structure interlaced with multilayer
chromosomal DNA is often associated with histone proteins to form a structural core, termed the nucleosome. Each nucleosome consists of a 147-base-pair DNA wrapped around an octamer of histones made up of a pair of H2A and H2B dimers, as well as a pair of H3 and H4 dimers. Between two nucleosomes, DNA not associated with nucleosomes (coined ‘linker DNA’) often associates with H1 histone proteins. This interaction is possible as DNA is negatively charged and is able to form tight binding with positively charged histone proteins (rich in basic lysine and arginine residues). As DNA replication and transcription during gene expression is dependent on the accessibility of replication and transcriptional machinery to DNA sites, nucleosomes thus serve as a form of steric hindrance that impede the access of such machinery. The relative packing of DNA with nucleosomes will determine the overall accessibility of DNA, defining two major regions termed ‘euchromatin’ and ‘heterochromatin’. Euchromatin is defined as chromatin that is less tightly packed and highly involved in transcription, whereas heterochromatin represents the opposite. The dynamic transition between a euchromatin and heterochromatin state is highly dependent on epigenetic modifications that occur on the DNA sequences or on amino histone tails. In this review, for didactic purposes, these epigenetic modifications and mechanisms can be broadly categorized into DNA methylation, histone modifications and microRNA involvement. The overall epigenetic tags that are imprinted across the genome is termed the ‘epigenome’, which can be identified as microdomains residing within the nucleus, which in turn will regulate the overall DNA structure and accessibility to provide differential patterns of gene expression. In simpler terms, the overall epigenome can be viewed as a tug-of-war, in which different epigenetic tags will either regulate positive or negative gene expression, and the sum of this dynamic interaction will determine the direction of gene expression.

**DNA methylation**

At the DNA sequence level, DNA methylation is one of the most well-studied epigenetic modifications. An epigenetic tag involves the covalent attachment of a methyl group to a cytosine ring at carbon position 5 (Figure 1). While cytosine is one of the principal conserved residues present throughout DNA, DNA methylation does not occur on every cytosine residue in the genome. Rather, the process of DNA methylation is biased, occurring only in regions termed CpG dinucleotide islands. These islands are recognized by stretching over more than 500 base pairs of DNA, with guanine and cytosine composition to be above 55% frequency, as well as an overall observed frequency ratio of CG:GC to be at least 0.6. These CpG islands are normally located in the promoter region of genes, which also tends to make up the 5' gene transcript. Besides that, it
has been recently identified that while CpG islands exist throughout the genome, their relative density differs across different positions. Another term, coined the ‘CpG shores’, 2kb downstream of Cpg Islands, there exists a much lower density of Cpg sites termed Cpg shores. These Cpg shores contain DNA methylation sites, which challenges conventional norm that DNA methylation only occurs at high density CpG sites. As such, DNA methylation does not only occur at high-density CpG islands, but also at locations that contain low-density CpG residues, which challenge conventional understanding of this relatively important and well-known epigenetic tag mechanism.

DNA methylation is often associated with transcriptional inactivation. The addition of a methyl group to CpG sites can prevent gene transcription via various mechanisms. DNA methylation can directly prevent the binding of DNA-binding factors to transcriptional sites. Moreover, the addition of methyl groups to CpG sites can be recognized by a family of proteins termed ‘methyl-CpG-binding domain (MBD) proteins’. Binding of these proteins to methylated CpG sites will in turn recruit histone or chromatin-modifying complexes, which in turn will assemble a spectrum of complexes that centrally mediate the repression of gene transcription. The addition of methyl groups to CpG sites is mediated by DNA methyltransferase (DNMT) family member enzymes. Of the five family members reported within this family of enzymes, only DNMT1, DNMT3a and DNMT3b possess enzymatic activity. By transferring a methyl group from S-adenosyl methionine to DNA, DNMT3a and DNMT3b are primarily involved in de novo methyl group transfer, whereas DNMT1 is involved in the maintenance of DNA methylation status in the epigenome. The cellular reservoir of S-adenosyl methionine is maintained by another group of enzymes called ‘methylene tetrahydrofolate reductases’ (MTHFRs).

Histone modifications

Histones that form part of the nucleosome structure represent a globular structure with their amino terminal tail protruding from each subunit. These histone tails are subjected to a myriad of post-translational modifications, such as methylation, acetylation and phosphorylation. These post-translational modifications of histone tails play various critical functions, regulating important aspects of chromatin packing and organization, transcriptional activation or repression, DNA repair, as well as telomere maintenance. Compared to DNA methylation, histone modification represents a relatively short-term reversible change that is especially sensitive to external stimuli changes. As different histone modifications confer different cellular outcomes, the distinct expression of total histone modifications, termed the ‘histone code’, will in turn determine the sum of the total interacting changes in response to a particular stimulus to produce the overall cellular outcomes.

Acetylation of histones

Acetylation of histone tails has been widely investigated for its role in influencing chromatin accessibility as well as gene expression. The covalent addition of acetyl groups to histone tails at the epsilon-amino group of conserved lysine residues is regulated by a family of writer enzymes termed histone acetyltransferases (HATs) (Figure 2). It has been generally described that histone acetylation is associated with a permissive chromatin state and drives transcriptional activation.
may be achieved via the synergistic interaction with nucleosome remodelling complexes, such as the SWI/SNF-like ATPase family members with HATs. Nucleosome remodelling may result in the sliding of nucleosome away from DNA through weakening of DNA–histone interaction, thereby promoting the accessibility of DNA to transcriptional machineries. On the other hand, the removal of acetyl groups is regulated by eraser enzymes known as histone deacetylases (HDACs). Unlike histone acetylation, effects of histone methylation on gene transcription are still unclear. Both transcriptional activation and deactivation have been reported to be associated with histone methylation.

**Figure 2.** Histone acetylation. Histone acetylation occurs at the amino termini of histone tails, and is mediated by a class of enzymes termed histone acetyltransferase (HATs). Subsequent removal of an acetyl group is mediated by another class of enzyme called histone deacetylases (HDACs). Histone acetylation is commonly associated with permissive chromatin accessibility and transcriptional activation.

**Figure 3.** Histone methylation normally shows preference at either lysine or arginine residues of histone tails. Addition of methyl groups to these residues is mediated by either lysine or arginine methyltransferases, respectively. Methyl group addition to arginine residues can either be symmetrical or asymmetrical, and is mediated by several subfamily members of arginine methyltransferases. Unlike histone acetylation, effects of histone methylation on gene transcription are still unclear. Both transcriptional activation and deactivation have been reported to be associated with histone methylation.

**Methylation of histones**

Histone methylation represents another form of histone modification that also helps to regulate chromatin accessibility and the level of gene expression (Figure 3). Compared to DNA methylation, methylation at histone levels occurs at the amino terminal tails, and the effects on gene expression are often reversible and complex.
The addition of methyl groups onto the histone amino terminal tails normally occurs at either lysine or arginine residues. However, given the conservative nature of residues that are able to be methylated, it has been generally observed that histone methylation occurs at different positions, and the effects generated are often dependent on the positions of the residues being methylated. Besides that, at a specific residue, the addition of methyl groups can be mono-, di- or trimethylated at lysine residues, whereas in the case of arginine residues it can either be mono- or dimethylated. Dimethylated arginine residues have another layer of complexity, where the methylation can either be in a symmetrical or asymmetrical topology. As a result, given the possible permutations and combinations of methylation patterns, it is therefore difficult to predict the effects of histone methylation on the transcription of genes. Despite the complexity of the mechanisms governing histone methylation, it has been widely reported that certain well-known methylation marks have been associated with transcriptional activation and repression. For instance, methylation at histone 3 lysine 4 is generally associated with transcriptional activation, whereas methylation at histone 3 lysine 9 is transcriptional repressive. Furthermore, the reversible nature of histone methylation and demethylation is mediated by the dynamic interaction between lysine or arginine methylases or demethyltransferases. The coordinated action and interplay between these readers and erasers will lead to diverse methylation marks, which in turn will regulate gene expression spatially and temporally.

MicroRNAs

MicroRNAs (miRNAs) represent an important emerging player in the field of epigenetics, involving precise interaction with specific genes and the ability to modulate the level of gene expression. miRNAs belong to a class of short non-coding RNAs, which exert their action at the post-transcriptional level, and are an important fine-tuner in the control of gene expression. Biogenesis of miRNAs is often complicated and involves multi-sequential steps (Figure 4). miRNA genes are first transcribed in the nucleus by RNA polymerase II into a primary transcript. This primary transcript, termed primary miRNAs (pri-miRNAs), is often very large and contains multiple miRNA genes occupying various loci across the pri-miRNAs. Following this, these pri-miRNAs will undergo micro-processing by a class of
RNaseIII enzymes called a Drosha/DGCR8 complex. This process will result in the generation of shorter hairpin–loop structures, called ‘precursor miRNAs’ (pre-miRNAs). Subsequently, pre-miRNAs will be exported out of the nucleus into the cytoplasm via the action of Exportin-5 protein. In the cytoplasm, pre-miRNAs will undergo a second round of cleavage by another RNaseIII enzyme termed ‘Dicer’, which will produce a duplex of the mature miRNAs. To mediate its biological activity of gene silencing, this duplex of mature miRNAs will undergo asymmetrical unwinding by the Dicer/TRBP complex, where a single strand of the mature miRNAs will then associate with a ribonuclear particle to form the RNA-induced silencing complex (RISC). The mature miRNAs in the RISC complex have been found to commonly recognize the 3′ untranslated region (3′ UTR) of the mRNAs, which may suppress protein synthesis or mediate mRNA degradation. miRNAs recognize a myriad of mRNAs simultaneously and work differently in a cell-context-dependent manner. As such, studies investigating the roles of miRNAs in diseases need to understand the complicated regulatory network that miRNAs operate.

Epigenetic regulation of inflammation in stroke

DNA methylation and inflammation in stroke

Using in vitro experiments, an ischaemic insult to cultured cells results in hypomethylation in the global genomic landscape. However, depending on the temporal aspect of stroke progression, certain regions of the genome experience enhanced DNA methylation. These results may reveal a temporal regulation of DNA methylation in response to stroke, which may play different roles in neurotoxicity and neuroprotection. Besides that, studies have shown that a low level of methylation in blood LINE-1 repetitive sequences is associated with higher stroke risk and poorer prognosis and mortality. Recent studies have reported that hypomethylation of LINE-1 DNA sequence is associated with higher VCAM-1 levels, which may promote stroke-induced inflammation and thereby exacerbate stroke injury. Hypomethylation of CpG sites of TNF receptor associated factor 3 (TRAF3) is also associated with enhanced platelet congregation in patients receiving clopidogrel (an antiplatelet drug), thus increasing the recurrence of ischaemic stroke. Conversely, hypermethylation of the thrombospondin-1 (THBS1) gene promoter region leads to gene silencing. THBS1 is secreted by platelets and is an inflammatory mediator needed to induce angiogenesis during cerebral ischaemia, which leads to neurorepair. Gene silencing of THBS1 via DNA methylation during stroke prevents neurorepair, thus exacerbating stroke injury. Similarly, another study has shown that methylation of protein phosphatase magnesium dependent 1A (PPM1A), which is involved in the inflammatory healing process, have led to increased risks of vascular recurrence in stroke patients who are treated with aspirin. As such, epigenetic modulation of DNA methylation during stroke may regulate inflammatory damage and repair processes during stroke injury, as well as subject patients to chronic inflammation that further increases stroke recurrence. However, other studies have reported contradictory results that no significant changes were observed in global DNA methylation status in large-artery atherosclerosis stroke, small-artery disease stroke, as well cardio-aortic embolism stroke. As such, DNA methylation may be confounded by different pathologies. Careful consideration and further studies are needed to gain a deeper understanding of the roles of DNA methylation in different stroke subtypes. Nonetheless, it has been recently proposed that the level of DNA methylation correlates with the chronological age of patients and serves as a good prognostic marker to assess stroke risk.

It has been reported that DNMT3a is responsible for degeneration of motor neurons in vitro using cultured NSC34 cells. Moreover, both DNMT1 and 3a are upregulated during induced apoptosis of NSC34 cells. Using the DNMT inhibitor RG108 in vitro, methylation of CpG sites is also inhibited with the concomitant blockage of apoptosis...
of motor neurons. However, this study is being conducted with the amyotrophic lateral sclerosis mechanism in mind. Moving forward, it will be interesting to investigate the roles of DNMT in neuronal cell death or glial cell activation following ischaemic stroke. DNA methylation is also reported to regulate differentiation and maturation of various cell types. Post-mitotic neurons are highly enriched in DNMT1 and DNMT3a. While studies have linked these enzymes to synaptic plasticity in learning and memory, further studies are required to investigate the roles of these enzymes in the neuronal response in ischaemic stroke. Furthermore, it has been established that enhanced expression of DNMT1 in macrophages leads to downregulation of peroxisome-proliferator activator receptor gamma (PPARγ), which helps to upregulate the expression of proinflammatory cytokines that drives atherosclerosis in mice. Another study also reported that DNA methylation profiles represent a useful biomarker to assess atherosclerotic progression in the human aorta. This lends useful insight on the roles of DNA methylation in association with atherosclerosis pathogenesis, which is a major risk factor for ischaemic stroke. In a mouse model of ischaemic stroke, mild ischaemic insult resulted in upregulation of DNA methylation, which is correlated with poor stroke outcome. Inhibition of DNMT resulted in neuroprotection from this mild ischaemic damage. However, using another stroke model that encapsulates excitotoxicity and necrotic death, DNMT is not involved in stroke outcome. These findings may highlight the potential roles of DNMT in mediating pathological outcomes in response to various degrees of ischaemia, and also the importance of variability in studying epigenetics using different stroke models. Furthermore, DNMT1 has been discovered to regulate the crosstalk between major immune signalling pathways, such as T-cell receptor (TCR) and B-cell receptor (BCR) pathways. DNMT1 downregulates the activity of TCR/BCR pathways, which drives immunosuppression in cardiovascular disease and stroke, which may explain the higher risks of infection associated with post-stroke patients.

In addition, methylenetetrahydrofolate reductase (MHTFR) has also been implicated to trigger inflammatory responses and thereby is correlated with increased stroke risk. MHTFR is an enzyme responsible for the catalytic regeneration of methionine, which eventually is required as a methyl donor for DNA methylation. For many years, it has been widely investigated that individuals exhibiting polymorphism of C677>T demonstrate hyperhomocysteinemia, a condition characterized by accumulation of homocysteine, a product formed following DNA methylation. MHTFR is responsible for the reconversion of homocysteine to methionine. However, individuals possessing this genetic variant lack the ability to regenerate the methyl reservoir, leading to the build-up of homocysteine. Interestingly, individuals possessing this genetic variant often have increased risk of cardiovascular and stroke events. Elevation in the homocysteine level is able to induce a plethora of inflammatory responses within the cerebral territory. Within endothelial cells of the vasculature, high levels of homocysteine are able to induce oxidative stress, as well as generate a myriad of proinflammatory mediators such as TNF and inducible nitric oxide synthase (iNOS). Together, hyperhomocysteinemia is able to drive the pathogenesis of endothelial dysfunction, which promotes the development of cerebral vascular damage and increases the risk of stroke. However, in other studies, MHTFR polymorphism association with stroke risk is contradictory. In one study conducted on the Black Sea Turkish population, MHTFR polymorphism did not seem to influence the risk of ischaemic stroke. Moreover, in a North Indian population, MHTFR polymorphism was also not correlated with ischaemic or haemorrhagic stroke risk. Besides that, this observation is consistent with results reported in Central and Northern Europe, whereas in Italy, MHTFR polymorphism is associated with ischaemic stroke risk. The presence of heterogeneous observations with regards to MHTFR polymorphism and stroke risk may be due to confounding factors like ethnicity, as well as inconsistency in the sample size within the populations studied. Interestingly, while genetic variants may account for the manifestation of hyperhomocysteinemia, it has also been discovered that the level of homocysteine within the body is epigenetically regulated. In one study, a young patient with a reported case of concomitant Crohn’s disease and C677>T polymorphism displayed increased inflammation, as well as deficiency in vitamin B6 levels. This patient subsequently developed a large-artery stroke, highlighting that the increased risk of stroke may be confounded by other factors.
Many factors have since been identified to modify the serum level of homocysteine, including lifestyle factors (e.g. age, smoking, diet and drugs). For instance, low vitamin (e.g. B<sub>6</sub> and B<sub>12</sub>) and folate levels and migraine have been associated with increased risk of stroke. As such, many studies have started to investigate whether modifying these environmental factors might also modify the plasma level of homocysteine, and thus provide an epigenetic approach to attenuate stroke risk. It has been reported that an appropriate intake of vitamins, antioxidants, as well as folic acid supplementation, confers protection against stroke. However, one group reported that DNA methylation of the MTHFR gene that mediates vitamin B<sub>12</sub> and serum folate levels increased the risk of ischaemic stroke. As such, it is still unclear whether the association of MTHFR with stroke risk is due to the deficiency of these dietary cofactors or the epigenetic regulation of MTHFR that leads to these deficiencies in the serum. More studies need to be undertaken, but clinical trials have started with these dietary cofactors in stroke prevention.

Histone acetylation and deacetylation in stroke

Using in vitro studies on murine and rat neuroglial cells, it has been shown that the administration of HDAC inhibitor trichostatin A helps to drive proinflammatory responses such as the upregulation of IL-6, iNOS and TNF. This proinflammatory response is attenuated via inhibition of NF-κB, which suggests that the modulation of histone acetylation status in microglial cells could act through an NF-κB-dependent manner to drive the proinflammatory response. Another group has also reported that acetylation at histone 3 lysine 9 (H3K9Ac) is upregulated in the ischaemic territory and is associated with microglial activation. Inhibition of HDAC in an in vitro model found that H3K9Ac upregulation leads to decreased expression of proinflammatory genes like TNF, IL-6, iNOS and STAT1, as well as an increase in anti-inflammatory genes like IL-10 and STAT3. The overall effect improved neuronal survival consistent with a neuroprotective action of HDAC inhibitors. Notably, it has been reported that trichostatin A-mediated neuroprotection via HDAC inhibition was not present in gelsolin-deficient mice after ischaemic stroke. It was also demonstrated that trichostatin A-mediated HDAC inhibition was highly dependent upon the expression of gelsolin, in addition to NF-κB. Furthermore, in a rat model of intracerebral haemorrhage, administration of the anti-epileptic drug valproic acid (VA) reduces inflammation and brain injury. Such changes were mediated via an interaction of VA with HDAC, leading to its inhibition. Moreover, in a rat model of focal cerebral ischaemia, VA administration was reported to ameliorate blood–brain barrier disruption and subsequent brain oedema through the downregulation of matrix metalloproteinase 9 (MMP-9), tight junction degradation, and the NF-κB pathway via suppression of HDAC. Moreover, another HDAC inhibitor, sodium butyrate, is reported to downregulate proinflammatory mediators IL-1β and IL-18, and increase expression of the neuroprotective protein insulin growth factor 1 (IGF-1) in ischaemic stroke. In a rat model of permanent ischaemic stroke, the post-stroke injection of HDAC inhibitors, sodium butyrate, trichostatin A or VA, improved functional outcome. This amelioration of stroke-induced tissue injury was mediated through inhibition of H3 histone deacetylation, which in turn reduced inflammation as assessed by microglia number and activity, and expression of proinflammatory markers. HDAC inhibitors also upregulated expression of heat shock protein 70 (Hsp70), a neuroprotective protein, and reduced expression of phosphorylated AKT, p53, iNOS and cyclooxygenase-2, in the ischaemic territory. Importantly, these inhibitors conferred protective benefits when administered at around 3 h after stroke onset, which is a potentially relevant therapeutic window for use in humans.

It has been established that ischaemic stroke causes a drastic reduction in H3 acetylation. Treatment with another HDAC inhibitor, suberoylanilide hydroxamic acid (SAHA), prevents this reduction in neurons and astrocytes and improves stroke outcome. Consistent with the previous study, SAHA treatment resulted in upregulation of Hsp70 and the anti-apoptotic Bcl-2, as well as reduced expression of proinflammatory markers such as IL-1. Similarly, it has been reported that stroke induces a drastic decrease in histone 3 lysine 9 lysine 14 acetylation (H3K9K14Ac), with a myriad of genes also dysregulated, particularly those associated with HDAC3. Again, administration of the HDAC
inhibitor, SAHA, reduces the level of neuroinflammation and ischaemic cell death.\textsuperscript{107}

It is important to note that the epigenetic status of one cell type in the ischaemic territory may also influence the activity of neighbouring cells. Microglial activation can influence the reduction in acetylation of H3 and H4 histones in astrocytes, thereby leading to the downregulation of astroglial nuclear factor-erythroid 2-related factor 2 (Nrf2), a mediator important in anti-oxidant defence in astrocytes.\textsuperscript{108} Treatment with the HDAC inhibitor VA or the GSK3\(\beta\) inhibitor lithium can restore the level of acetylation and thereby maintain anti-oxidant defence previously suppressed due to inflammation.\textsuperscript{108}

It is important to note that the HDAC family described in the studies above consists of many members. While HDAC inhibitors have been shown to be protective against stroke-induced damage, most studies using HDAC inhibitors did not investigate drug specificity against individual HDAC members. In a study of focal cerebral ischaemia induced by photothrombosis, HDAC inhibition using trichostatin A was ineffective in HDAC2 knockout mice.\textsuperscript{109} Functional improvement in stroke outcome was observed when HDAC2 was present, and inhibition of HDAC2 using SAHA improved functional recovery.\textsuperscript{109} This demonstrates the importance of considering the roles of individual HDAC members in stroke pathogenesis. Moreover, using RNA interference, another group found in overexpression and mutant studies that HDAC4 forms a complex with nuclear hormone receptor corepressor (N-CoR).\textsuperscript{110} Together, this complex is then able to induce the recruitment of monocyte enhancer factor 2 (MEF2) transcription to regulate IL-2 expression.\textsuperscript{110} Likewise, HDAC11 regulates expression of IL-10 in antigen-presenting cells.\textsuperscript{111} HDAC3 has been reported to contribute to neurotoxicity-induced death of neurons, such that inhibiting HDAC3 with IGF-1, or inhibiting GSK3\(\beta\), ameliorates this neurotoxicity.\textsuperscript{112} Thus, different HDAC members appear to operate differently across cell types and via varying mechanisms of action. As such, understanding how specific members of HDAC regulate expression of inflammatory mediators will be critical to inform the development of drugs to target epigenetic mechanisms in stroke. Overall, it appears that inhibition of HDAC during cerebral ischaemia confers neuroprotective effects via multiple mechanisms.

The concepts of ischaemic preconditioning and the induction of ischaemic tolerance have recently gained increased interest. Briefly, it has been hypothesized that an intentional ischaemic insult to the brain will induce a plethora of genetic reprogramming resulting in a state of tolerance that will limit the pathogenesis following a subsequent stroke. Such changes in gene expression are thought to confer a neuroprotective effect to reduce the risk and damage associated with stroke.\textsuperscript{113} Regarding epigenetics, ischaemic preconditioning has been reported to induce a pro-acetylation status in H3 and H4 histones, which is neuroprotective during cerebral ischaemia. Many strategies have been utilized to induce ischaemic preconditioning. One example of induction of ischaemic tolerance is the chronic dietary intake of acetate.\textsuperscript{114} It has been reported that acetate supplementation promoted the acetylation of H3K9, H4K8 and H4K16.\textsuperscript{114} Acetylation at these sites has been shown to reduce neuroglial inflammatory responses, as well as the secretion of pro-inflammatory cytokines like IL-1\(\beta\).\textsuperscript{114} Besides this method, other approaches have been investigated and are reviewed elsewhere.\textsuperscript{115}

The level of histone acetylation during stroke is also an important determinant for functional recovery. Stroke patients may suffer from memory and cognitive impairment,\textsuperscript{116} and HDAC2 has been reported to be a negative regulator of learning and memory, as well as of synaptic plasticity.\textsuperscript{117} Treatment with HDAC inhibitors activates the downstream cAMP response element binding protein (CREB): CREB-binding protein (CBP) complex, which promotes memory formation.\textsuperscript{118} In rats subjected to stroke, administration of apigenin inhibits HDAC and promotes upregulation of memory formation mediators such as CREB and brain-derived neurotrophic factor (BDNF).\textsuperscript{119} Further, cognitive impairment in post-stroke dementia (PSD) – another common pathology in stroke patients\textsuperscript{120} – can be ameliorated by treatment with the flavonoid icariin, which promotes histone acetylation in mice.\textsuperscript{120} Thus, while HDAC may be an important mediator of inflammatory responses during stroke, targeting HDAC may attenuate inflammatory damage and promote functional outcome. In contrast, HDAC4 has been reported to be a positive
regulator of learning and memory formation. Thus, specific members of the HDAC family appear to operate in a differential manner, and careful consideration needs to be given when targeting HDAC members in order to avoid toxicity.

**Histone methylation and demethylation in stroke**

Stroke outcome is known to be variable in adult and middle-aged rodent models, in association with functional impairment of astrocytes with increasing age that may be related to histone modifications. Following ischaemic stroke, histone 3 lysine 4 trimethylation (H3K4me3) is more highly enriched in astrocytes of young adults than in middle-aged rats. Histone methylation in a site-specific pattern results in more highly packed chromatin, leading to modulation of vascular endothelial growth factor and microRNA-20 expression. Besides providing insight as to how age may affect the severity of stroke, histone methylation at different sites may also differentially affect downstream gene expression. As such, investigation into the relative expression of histone methylation tags in stroke may allow us to decipher more detail about the molecular mechanisms governing the pathogenesis of stroke.

Using an *in vitro* neuronal model of stroke, inhibition of H3K9 methyltransferase enzymes, G9a and SUV39H1, using chaetocin and RNA interference demonstrated neuronal resistance to cell death, potentially mediated by more active transcription of BDNF at its promoter site. Furthermore, during rat transient global cerebral ischaemia *in vivo*, levels of lysine-specific demethylase 1 (LSD-1) are reported to correlate with H3K4 mono-, di- and trimethylation levels in the brain. Interestingly, LSD-1 expression differs spatially and temporally following cerebral ischaemia, which may highlight the particular vulnerability of specific areas of the brain to stroke injury. Moreover, mild to moderate ischaemia perturbs the activity of histone lysine methylases (KMTs) and histone lysine demethylases (KDMs), thereby leading to a global reduction in histone lysine 9 dimethylation (H3K9me2) in the striatum. Treatment with dimethylolglycine (DMOG), an inhibitor of KDM4 or JMJD2 types of histone lysine demethylases, increases expression of H3K9me2 with concomitant improvement in neurological function after stroke. Modulation of histone methylation levels may thus be a potential target to regulate stroke-induced damage or recovery. Furthermore, many studies also demonstrate a link between histone lysine methylases and demethylases in inflammation. TNF is reported to reduce methylation of H3K9 and H3K27, which is involved in the upregulation of ICAM-1 in cerebral vessels. Using both inhibitor and overexpression studies, it has been shown that G9a lysine methylases and KDM4B lysine demethylases are implicated in modulating the level of methylation at these two sites, which mediates the influence of TNF on expression of either ICAM-1 or VCAM-1, thereby affecting neutrophil infiltration. Notably, in human stroke patients, the levels of serum TNF are reported to be correlated with H3K9Ac and H3K4me3, which may influence stroke outcome. Clearly, epigenetic mechanisms represent complex processes that may be impacted by other histone modifications. HDAC inhibition has been reported to increase H3K4me2 at the Hsp70 promoter region in neurons and astrocytes. As such, epigenetic modulation of a specific histone mark may not be sufficient to induce a change, but rather it may be more useful to consider interactions relevant to the status of the entire epigenome.

Besides histone lysine methylation, histone arginine may also play an inflammatory role that exacerbates stroke injury. It has been reported that rats with hyperhomocysteinemia have relatively low levels of asymmetric monomethylarginine (ADMA). As hyperhomocysteinemia is associated with increased inflammation and stroke risk, findings of hypomethylation of histone arginine residues in association with hyperhomocysteinemia may warrant further study. Another group has provided evidence of a more direct role of histone arginine in ischaemic stroke, in which levels of ADMA and symmetric monomethylarginine (SDMA) are highly expressed. ADMA, a well-known NOS inhibitor, may not only contribute to reduced cerebral blood flow, but also oxidative stress and excitotoxicity-mediated neuronal death, to exacerbate damage from ischaemic stroke. As such, the levels of ADMA could be a biomarker of ischaemic stroke damage. ADMA and SDMA levels have also been associated with the expression of inflammatory mediators following ischaemic
stroke, such as monocyte chemotactic protein-1 (MCP-1), MMP-9, tissue inhibitor of matrix metalloproteinase-1 (TIMP-1), IL-6, C-reactive protein and S100B. Interestingly, the expression of these mediators correlates with histone arginine methylation, which could explain a relationship with inflammation in stroke.

Thus, while conventional therapeutics have been targeted for direct intervention against neutrophil transmigration without success, future studies might instead be redirected towards the modulation of critical histone writers and erasers to target stroke inflammation.

MicroRNAs and inflammation in stroke

MicroRNAs have been implicated in various aspects of stroke pathophysiology, including excitotoxicity, oxidative stress, apoptosis and inflammation. The roles of miRNAs in regulating inflammation during stroke will be discussed here. In stroke patients with intracerebral haemorrhage, both spatial localization and expression levels of a wide array of miRNAs have been reported to be altered. In adult rats subjected to focal cerebral ischaemia, expression of miR-124a, one of the more highly enriched miRNAs in the brain, was reduced in neural progenitor cells in the subventricular zone of the brain. This expression pattern of miR-124a was accompanied by increased activation of Notch signalling. Using an in vitro neural progenitor cell model, miR-124a was found to regulate stroke-induced neurogenesis with an involvement of Notch signalling.

Another study using a rat model of ischaemic stroke reported that miR-124 is upregulated in the plasma and may thus be a useful biomarker for stroke injury. In human ischaemic stroke patients, blood levels of miR-30a and miR-126 were reduced for 24 weeks. Interestingly, another microRNA, let-7b, was found to display a differential pattern of expression across different stroke subtypes. Let-7b was lower in stroke patients of a large atherosclerosis subtype compared to non-stroke patients, whereas in other types of ischaemic stroke, let-7b was higher than in healthy individuals. The screening of different types of microRNAs may thus serve as a useful tool to assess the risks and prognosis of specific stroke subtypes. Indeed, expression of different microRNAs following stroke varies considerably in a tissue-dependent and stroke-subtype manner, coinciding with earlier findings that miRNAs work in a context-dependent setting. As such, future studies need to carefully consider the potential roles that these miRNAs may contribute to stroke before further targeted interventions are developed.

miRNAs have been demonstrated to regulate various aspects of thrombus formation, which may thus contribute to the early phase of neuroinflammation following stroke. miR-19a, which has been reported to be reduced following ischaemic stroke, is associated with tissue factor pathway inhibitor (TFPI) and plasminogen activator inhibitor 1 (SERPIN1), as well as tissue factor III that modulates thrombus formation. Furthermore, other prominent downregulated miRNAs that were associated with the modulation of other clotting mediators and identified to be altered in ischaemic stroke include miR-let-7i, miR-122 and miR-148. Overall, downregulation of these miRNAs would be expected to promote blood clotting, and thus facilitate thrombus formation in the early phase of the inflammatory cascade during stroke. As such, therapies targeted at increasing levels of these miRNAs could prevent re-occlusion due to blood clotting.

Initiation of the inflammatory cascade occurs with the release of inflammatory mediators by resident brain cells such as microglia. In the ischaemic territory, these activated cells release mediators that propagate inflammatory damage. Although these inflammatory mediators display potential for use as biomarkers of neuroinflammation and mediators of injury during stroke, therapeutics to target them have not been successful. However, recent studies have shown that miRNAs play an important role in modulating the expression and release of inflammatory mediators in a cell-dependent manner, which was previously poorly understood. miR-155 is well known to be a proinflammatory miRNA, and it is heavily involved in the inflammatory process during stroke. It has been implicated as a regulator of macrophage differentiation and phenotype determination and its presence is necessary for macrophages to adopt a proinflammatory status. Moreover, miR-155 is necessary to induce proinflammatory signalling in microglia, where it is reported to downregulate suppressor of cytokine signalling 1 (SOCS-1) protein, resulting in microglial inflammation via upregulation of...
Inflammatory molecules such as iNOS.

Inhibition of miR-155 using oligonucleotides reduces both inflammation by microglia and neuronal apoptosis. Furthermore, miR-155 promotes secretion of both TNF and IL-1β via signalling of NF-κB and toll-like receptor 4 (TLR-4), and downregulation of myeloid differentiation primary response gene (MyD88). Again, in mice following ischaemic stroke, treatment with the miR-155 antagonist, acetylbritanilactone, resulted in a reduced infarct volume through decreased expression of proinflammatory molecules, and a concomitant improvement in neurological score, thereby exerting a neuroprotective function. As such, miR-155 is considered to be damaging during stroke, and future studies should seek to develop an antagonist that is translatable into humans. Another microRNA that is associated with proinflammatory effects in stroke is miR-210. Treatment with an miR-210 inhibitor in mice subjected to MCAO stroke resulted in an overall decrease in expression of proinflammatory cytokines such as TNF, IL-1β and IL-6, as well as chemokines like CCL2 and CCL3. This was associated with reductions in cerebral infarct volume and neurological impairment.

Interestingly, it has been demonstrated that inflammasome activity may be regulated via the action of miRNAs. The inflammasome is a cytosolic complex known to play a role in ischaemic stroke by promoting inflammatory and cell death mechanisms. Roles for NLRP1 and NLRP3 inflammasomes and caspase-1 activation are well established in ischaemic stroke-induced neuroinflammation. It was shown that following intracerebral haemorrhage, miR-223 can suppress the NLRP3 inflammasome by binding to its 3′ UTR sites. As a result, both caspase-1 activation and IL-1β release were inhibited, leading to reduced brain oedema and improved neurological scoring following stroke. That study provides novel insight in that microRNAs may not only regulate cytokine secretion directly, but also indirectly regulate their expression, such as through inflammasomes. As such, certain microRNAs seem to be closely associated with inflammatory responses in stroke and may reveal the mechanism behind the spatial and temporal control of these proinflammatory cytokines and chemokines action. Conversely, as compared to miR-155, miR-let-7a has been implicated in anti-inflammatory responses mediated by microglia during stroke. miR-let-7a has been found to induce upregulation of anti-inflammatory mediators and recovery molecules, such as IL-4, IL-10, BDNF in microglia, as well as downregulate expression of proinflammatory iNOS and IL-6. While miR-155 may regulate microglial inflammatory activity, other miRNAs, such as miR-let-7a, may regulate the opposite activity. However, notably, it has also been reported that miR-155 can increase expression of the neuroprotective cytokine, IL-10. Nonetheless, it seems that miR-155 predominantly exerts proinflammatory effects in the brain during stroke. As such, microRNA agomirs and antagonists that can modulate the levels of critical miRNAs are likely to be important for maintaining anti-inflammatory influences in the ischaemic brain territory. Indeed, many studies have attempted to inhibit critical miRNAs involved in maintaining neuroinflammation in stroke, with results being promising so far.

It has been reported that microRNAs regulate the release of cytokines and chemokines, which activate endothelial cells and promote the extravasation and migration of neutrophils following cerebral ischaemia. Indeed, certain microRNAs appear to be responsible for regulating endothelial cell activation and expression of adhesion molecules, to facilitate leukocyte adhesion. For example, miR-146 is critical for controlling vascular inflammation by preventing endothelial activation via suppression of the NF-κB, mitogen activated protein kinase (MAPK) pathway, as well as downstream EGR transcriptional activity. Moreover, miR-31 and miR-17-3P are each induced by TNF and antagonize expression of E-selectin and ICAM-1. Inhibition of these microRNAs increased neutrophil adhesion to endothelial cells, whereas the microRNA mimetics prevented leukocyte adhesion. miR-126 is a widely studied microRNA involved in vascular inflammation and angiogenesis, and which is a proposed biomarker for ischaemic stroke. miR-126 is expressed by endothelial cells and inhibits VCAM-1 expression, thus modulating the level of vascular inflammation. Furthermore, in a Chinese population the presence of a polymorphism at a single site affecting the miR-491-5p binding site may lead to an increased risk of cerebral ischaemia. miR-491-5p antagonizes the expression of MMP-9, and so this alteration in
binding may affect miR-491-5p activity and upregulate MMP-9 expression to facilitate blood–brain barrier disruption and leukocyte extravasation.\textsuperscript{146} Another reported study indicated that a functional polymorphism in the 3′ UTR site of angiopoietin-1 gene leads to an alteration in the binding sites of miR-211, which in turn helps to reduce the risk of stroke occurrence.\textsuperscript{147} In addition, miR-107 has been reported to target Dicer-1, which upregulates expression of vascular endothelial growth factor (VEGF), which should then facilitate post-stroke angiogenesis and promote recovery.\textsuperscript{148} Thus, overall, different miRNAs appear to be able to differentially modulate various aspects of the maintenance of vascular function.

Epigenetic intervention in stroke

With the rise in numbers of studies focusing on epigenetic mechanisms, a revolution of information has emerged to inform a better understanding of neuroinflammation and neurotoxicity underlying stroke pathophysiology. Unfortunately, despite the elucidation of numerous molecular and cellular mechanisms that govern tissue injury following stroke, approved treatments for clinical stroke are limited to tissue plasminogen activator (tPA) and the recent introduction of mechanical thrombectomy.\textsuperscript{149} However, the significant time limitations that apply to the use of these treatment strategies (i.e. <4.5 h for tPA and <8 h for thrombectomy in patients on blood thinners or who have received rTPA), means that >80% of ischaemic stroke patients are essentially left untreated, providing an enormous impetus for new stroke therapies to be developed.

Epigenetics represent a novel area in the study of stroke, and we have discussed that various epigenetic tags can be useful for predicting stroke risk, outcome and recovery. The epigenome varies considerably across individuals, and is heavily dependent upon the myriad of environmental stimuli that an individual is exposed to throughout their lifetime. Due to the diverse combinations of interplaying factors, every individual will have a unique epigenetic code, which may result in varying degrees of stroke risk, outcome and recovery. This concept may provide a better explanation for the interindividual variability that manifests across different stroke patients. A related aspect influenced by epigenome status may be the degree of inflammation occurring in individual stroke patients. If so, it is plausible that future therapies could be developed to modify the epigenomic status occurring during stroke to push it towards a state of regeneration rather than inflammation. Indeed, certain lifestyle factors have been shown to influence stroke risk, and as such there are likely to be good life practices associated with good health and the avoidance of stroke due specifically to epigenetic mechanisms. Such practices may involve modulation of an individual’s epigenetic tags to promote neuroprotection and tissue regeneration. In this last part of the review, we shall briefly highlight some recent findings with epigenetic drugs developed in animal models, and some lifestyle practices with potential to protect against stroke incidence and/or improve recovery.

Drugs to modulate epigenetic mechanisms in stroke

Given that DNA methylation profiles change considerably during stroke, a focus has been directed towards investigating the roles of DNMTs in stroke pathology. DNMTs have been found to be heavily involved in mediating changes in global DNA methylation status, and there have been studies assessing DNMT inhibitors for amelioration of stroke outcome.\textsuperscript{76} For example, treatment of mice with a DNMT inhibitor, 5-aza-2′-deoxycytidine (also known as decitabine), conferred protection in a model of stroke.\textsuperscript{76} However, this DNMT inhibitor appears to be effective only in the context of mild ischaemic damage, and the beneficial effect was not replicated in a stroke model of excitotoxic/necrotic cell death.\textsuperscript{76} In a study using another DNMT inhibitor, zebularine, in a rat model of ischaemic stroke, this agent was reported to reduce neurological damage.\textsuperscript{39} Both decitabine and zebularine are cytosine analogues that are nonspecific in their pharmacological actions,\textsuperscript{39} which probably limits their usefulness in different stroke models and will slow their translational progress. As a result, there is a need to develop alternative drugs that are more specific, such as the MG98 antisense oligonucleotide, which shows specificity towards inhibiting mRNA translation of DNMT1.\textsuperscript{150–153} In addition, second-generation DNMT inhibitors, such as procainamide, hydralazine and VA, have also shown potential to modify the epigenetic machinery, which could
thus be useful as stroke therapeutics.\textsuperscript{150–153} However, while targeting epigenetic regulation through DNA methylation may yield more promising results than conventional therapies, such drugs have still only been shown to inhibit DNMT. Notably too, a reduced level of DNMT1 in post-mitotic neurons may confer neuroprotection during cerebral ischaemia, and in the absence of DNMT1 using mutant studies, neuroprotection is abrogated in mice.\textsuperscript{154} Thus, future research directed towards the development of DNMT inhibitors for stroke should consider the possible implications of total elimination of DNA methylation during stroke, including the broader complexities of DNA methylation epigenetics.

Besides DNMT inhibitors, it has been demonstrated more extensively that HDAC inhibitors can modify epigenetic programming in stroke and that this may ameliorate stroke injury.\textsuperscript{100,150,155–158} As discussed, prominent HDAC inhibitors in stroke research include VA, trichostatin A and sodium butyrate. These therapeutics have been widely tested in stroke models and have been consistently found to reduce ischaemic injury and to improve functional recovery.\textsuperscript{100,150,155–158} Besides the finding that HDAC inhibitors can modulate the histone acetylation machinery, it has also been discovered that HDAC inhibitors can attenuate proinflammatory pathways such as NF-\(\kappa\)B and MMP-9 activity during stroke.\textsuperscript{100,150,155–158} The amelioration of the inflammatory response in stroke through reprogramming histone acetylation reveals great potential for the use of epigenetic drugs in the treatment of stroke. In conjunction with these more prominent HDAC inhibitors, other drugs such as SAHA (or vorinostat), sodium 4-phenylbutyrate and entinostat have also been reported to provide neuroprotection against experimental stroke injury.\textsuperscript{105,159,160} Modulation of histone acetylation status might therefore be able to alleviate inflammation during stroke, as well as modulate a myriad of other relevant protective mechanisms.

With a sufficient level of understanding of the specificity of various miRNAs and their substrates, there is optimism about the plausibility of developing miRNA-epigenetic drugs. Indeed, the development of synthetic miRNA mimetics has already been employed in many studies, and has illuminated the spatial and temporal regulation of inflammation during stroke. As mentioned, miRNA agomirs are synthetic mimetics that perform a similar function to that of biological miRNAs \textit{in vivo}, whereas miRNA antagomirs act as inhibitors that prevent the action exerted by specific miRNAs.\textsuperscript{161,162} miRNAs that are neuroprotective tend to be downregulated in stroke, whereas other miRNAs that drive toxic inflammatory responses tend to be upregulated (Table 1). As such, future studies should assess the effects of delivering miRNA agomirs and/or antagomirs, as appropriate, to promote a neuroprotective microenvironment during stroke. In such a manner, miRNAs could serve as a regenerative medicine to be delivered to stroke patients, although until now there has been limited development in animals due to low delivery efficiency, bioavailability and half-life, as well as some cytotoxicity,\textsuperscript{163–168} and no studies have yet been performed in humans. It is too early to speculate as to the likely success of such an approach, but future studies might consider the general concept of targeting miRNA biosynthesis and degradation \textit{in vivo} system to modulate the levels of key miRNAs.

\textbf{Conclusion}

Stroke continues to be a major cause of death globally, and despite extensive research into the molecular and cellular mechanisms of its pathogenesis, the use of tPA administration and/or mechanical thrombectomy involve strict eligibility criteria that greatly limit their usefulness. While many molecular targets have been identified to mediate inflammation during stroke, very few clinical trials have provided evidence to support positive effects of anti-inflammatory treatment strategies in acute ischaemic stroke.\textsuperscript{169,170} The lack of major progress in these research attempts could be in part due to a lack of understanding of the spatial and temporal regulation of key molecular players in the inflammatory cascade. Further, owing to interindividual variation in the degree of vulnerability and extent of damage induced during stroke, it has been suggested that the epigenome status of an individual may be relevant for their ensuing stroke pathology. Indeed, through DNA methylation, histone modifications, and miRNAs, inflammatory mediators can be regulated in an epigenetic context. Epigenetic regulation also provides a rational explanation as to why stroke is such a complex disease, with the possibility that overall epigenetic tags are created from the
| Types of epigenetic modification | Model used | Outcome during stroke | Lesson learnt from studies | References |
|---------------------------------|------------|-----------------------|----------------------------|------------|
| DNA methylation                 | Neuronal culture | • Hypomethylation in global genome landscape. Certain areas of the genome exhibit DNA hypermethylation in a temporal context. | • Temporal regulation of DNA methylation is exhibited in an in vitro model of stroke. | Meller et al.61 |
| Human stroke patients           | Human stroke patients | • Hypomethylation of blood LINE-1 repetitive sequences. | • Associated with higher stroke risk, poorer prognosis and mortality. • Upregulation of VCAM-1, which may promote neuroinflammation during stroke. | Baccarelli et al.62,63 |
| Human stroke patients           | Human stroke patients | • Hypomethylation of CpG at TRAF3 sites is associated with increased platelet clotting in clopidogrel-treated patients, leading to increased risk of ischaemic stroke. | • Administration of antiplatelet drugs may modify DNA methylation profiles and affect stroke risk. | Gallego-Fabrega et al.64 |
| Abdominal aortic aneurysm mouse | Abdominal aortic aneurysm mouse | • Hypermethylation of THBS1 gene leads to decreased secretion of THBS1 during cerebral ischaemia. | • Downregulation of angiogenesis and neurorepair. | Vidigal and Ventura38 Lawler65 Lawler and Lawler66 Gutierrez et al.67 Res68 |
| Human stroke patients           | Human stroke patients | • Methylation of PPM1A is associated with increased vascular recurrence in stroke patients who are treated with aspirin. | • Administration of aspirin may modify DNA methylation profile and affect inflammatory healing process and stroke risk. | Gallego-Fabrega et al.69 |
| Human stroke patients           | Human stroke patients | • No global DNA methylation changes in large-artery atherosclerotic stroke, small-artery disease stroke, and cardio-embolic stroke. | • DNA methylation epigenetic programming differs across stroke subtypes. | Soriano-Tárraga et al.70 |
| Human stroke patients           | Human stroke patients | • DNA methylation correlates with chronological age of stroke patients. | • DNA methylation can be used as a good diagnostic and prognostic marker for stroke patients. | Soriano-Tárraga et al.71 |
| NSC34 motor neuron cell culture | NSC34 motor neuron cell culture | • DNMT1 and DNMT3a is upregulated induced apoptosis of NSC34 cells. • Administration of DNMT inhibitor R610B blocks methylation of CpG sites and the concomitant blockage of apoptosis of motor neurons. | • DNMT3a is responsible for degeneration of motor neurons. | Chestnut et al.72 |
| Knockout mice                   | Knockout mice | • DNMT1 and DNMT3a are highly enriched in post-mitotic neurons. • Studies have linked these enzymes to synaptic plasticity in learning and memory. | • Further studies need to be conducted on the roles of these enzymes in neuronal response in ischaemic stroke. | Feng et al.31,73 |
| Primary macrophage culture atherosclerotic mouse model | Primary macrophage culture atherosclerotic mouse model | • Enhanced expression of DNMT1 in macrophages downregulates PPARγ, which upregulates expression of proinflammatory cytokines to promote atherosclerosis in mice. | • DNMT1 in macrophages is responsible for the pathogenesis of atherosclerosis, which may be an early event of stroke manifestation. | Yu et al.74 |
| Types of epigenetic modification | Model used | Outcome during stroke | Lesson learnt from studies | References |
|---------------------------------|------------|-----------------------|----------------------------|------------|
| Human aorta sample              | • DNA methylation specific pattern identified for atherosclerotic progression. | • Studying specific DNA methylation profile can be a useful prognostic marker for atherosclerosis progression, which may be an early event of stroke manifestation. | Del Pilar Valencia-Morales et al. | |
| MCAO mouse model                | • Mild ischaemic insult to mice upregulates DNA methylation and is correlated with poor stroke outcome. | • DNMT plays a role in DNA methylation control of genes related to poor stroke outcome in MCAO mice. | Endres et al. | |
| Human stroke patients           | • DNMT1 participates in suppression of crosstalk signalling between TCR and BCR immune pathways in cardiovascular and stroke pathologies. | • DNMT1 may result in immunosuppression, which may help to explain higher infection risks associated with post-stroke patients. | Infarction77, Chamorro78 |
| Human stroke patients           | • C667>T MTHFR polymorphisms correlated with increased stroke risk. | • Interference with DNA methylation via disruption in homocysteine reservoir leads to hyperhomocysteinemia, which aggravates inflammatory responses and endothelial dysfunction and thereby correlates with higher stroke risk. | Alluri et al.33, Daniels et al.24, Zhou et al.75, Zhang et al.79, Kanth et al.80, Botto Lorenzo and Yang81, Trabetti82, Homocysteine Studies Collaboration83, Gao et al.84, Faraci and Lent85, Cronin et al.86, Goldstein87, Uçar et al.88, Somarajan et al.89, Younes-Mhenni et al.90, Sánchez-Moreno et al.91, Pezzini et al.92, Kelly et al.93, Sapoznik94, Zhao et al.95, Keat et al.96 |
| Histone acetylation and deacetylation | Murine and rat neuroglial cell culture | • Administration of HDAC inhibitor trichostatin A upregulates IL-6, iNOS and TNF-α expression, promoting inflammation. Inhibition of NF-κB ameliorates this proinflammatory response. | • Prevention of histone deacetylation via trichostatin A may act in an NF-κB-dependent manner to trigger proinflammatory responses in microglial cells. | Suuronen et al.97 |
| Types of epigenetic modification | Model used | Outcome during stroke | Lesson learnt from studies | References |
|----------------------------------|------------|-----------------------|----------------------------|------------|
| Ischaemic stroke rat model  | Microglial cell culture | • Upregulation of H3K9Ac in ischaemic territory associated with microglial activation.  
• Administration of HDAC inhibitor in vitro maintains H3K9Ac upregulation which decreases expression of proinflammatory genes TNF-α, IL-6, iNOS, STAT1, and increases expression of anti-inflammatory genes IL-10 and STAT3.  
• Neuronal survivability is improved with HDAC inhibition. | • H3K9Ac is responsible for neuroprotection via microglial activation is ischaemic stroke. | Suuronen *et al.*[^97], Patnala *et al.*[^98], Patnala *et al.*[^99] |
| MCAO mouse model | | • Trichostain-A mediated neuroprotective effects via HDAC inhibition are not observed in gelsolin-deficient ischaemic stroke mice. | • Trichostatin A mechanism of action is also dependent on the presence of gelsolin. | Yildirim *et al.*[^100] |
| Intracerebral haemorrhage stroke rat model | | • Administration of anti-epileptic drug (HDAC inhibitor) valproic acid reduces inflammatory responses and stroke-induced injury. Upregulation of neuroprotective markers such as Hsp70 and phosphorylated CREB. Downregulation of neurotoxic markers such as IL-6 and MCP-1. | • Prevention of histone deacetylation via valproic acid is neuroprotective in stroke via reduction in inflammatory responses and increase in neuroprotective mediator expression. | Sinn *et al.*[^101] |
| Focal cerebral ischaemia rat model | | • Administration of valproic acid ameliorates blood–brain barrier disruption and brain oedema via downregulation of MMP-9, tight junction degradation and NF-κB pathways. | • HDAC inhibition via valproic acid reduces compromise of endothelium which may prevent neutrophil migration and diapedesis. | Wang *et al.*[^102] |
| MCAO female rat model | | • Administration of sodium butyrate (HDAC inhibitor) downregulates proinflammatory IL-1β and IL-18 expression, and upregulates neuroprotective IGF-1. | • HDAC inhibition via sodium butyrate is neuroprotective in stroke via reduction in inflammatory responses and increased expression of neuroprotective mediators. | Park *et al.*[^103] |
| Permanent MCAO rat model | | • Administration of sodium butyrate, valproic acid or trichostatin A improves stroke outcome via inhibition of deacetylation of H3 histones, reduction in inflammation in microglia number and activity, as well as decrease in proinflammatory markers phosphorylated AKT, p53, iNOS and cyclooxygenase 2 in ischaemic territory.  
• Upregulation of neuroprotective Hsp70 was observed. HDAC inhibitors-induced neuroprotection observed around 3 h after stroke with chronic neurological improvement. | • HDAC inhibitors are neuroprotective in stroke via reduction in inflammatory responses and increased expression of neuroprotective mediators, as well as other mechanisms.  
• These HDAC inhibitors align with the therapeutic window for stroke patients, indicating translational potential. | Kim *et al.*[^104] |
| Types of epigenetic modification | Model used | Outcome during stroke | Lesson learnt from studies | References |
|---------------------------------|------------|-----------------------|---------------------------|------------|
| MCA0 mouse model                | • Stroke reduces H3 acetylation.  
• Administration of SAHA (HDAC inhibitor) in astrocytes and neurons maintains H3 acetylation and improves stroke outcome.  
• Upregulation of Hsp70 and Bcl-2 observed, with concomitant downregulation of proinflammatory IL-1. | • HDAC inhibition via SAHA is neuroprotective in stroke via reduction in inflammatory responses and increase in expression of neuroprotective mediators. | Faraco et al.105  
Langley et al.106 |
| ICAO mouse model                | • Stroke induces a drastic decrease in H3K9K14Ac.  
• Stroke induces dysregulation of genes associated with HDAC3.  
• Administration of HDAC inhibitor SAHA reduces neuroinflammation and ischaemic cell death. | • Decrease in H3K9K14Ac may trigger neuroinflammation and cell death, which may be ameliorated via SAHA-mediated HDAC inhibition. | Jhelum et al.107 |
| Microglial and astrocyte cell culture | • Microglial activation during neuroinflammation leads to decrease in acetylation of H3 and H4 histones in astrocytes, leading to downregulation of Nrf2, a mediator needed for anti-oxidant defence in astrocytes.  
• Administration of valproic acid or GSK3β inhibitor lithium restores acetylation level and thereby maintains anti-oxidant defence in astrocytes. | • Different cell types are able to modulate the epigenetic status of neighbouring cells in the ischaemic territory. HDAC or GSK3β inhibition is necessary to maintain anti-oxidant defence in astrocytes during neuroinflammation. | Correa and colleagues108 |
| Focal cerebral ischaemia mouse model | • Trichostatin A inhibition is ineffective in HDAC2 knockout mice. Functional improvement in stroke outcome observed when HDAC2 is present and inhibited by trichostatin A.  
• Results are replicated when HDAC2 is inhibited by SAHA. | • HDAC2 is responsible for determining functional outcome following stroke. | Tang and colleagues109 |
| Jurket, HEL, HEK293 and PEAKrapid cell culture | • Using RNA interference, mutant, overexpression and HDAC inhibitor studies, HDAC4 forms a complex with N-CoR to induce the recruitment of MEF2 transcription to regulate IL-2 expression. | • HDAC4/N-CoR complex is responsible for IL-2 expression. | Matsuoka and colleagues110 |
| Naïve CD4+ T cell culture        | • Loss of HDAC11 resulted in increased IL-10 production in activated macrophages. | • HDAC11 may function to downregulate IL-10 expression. | Georgopoulos111 |
| Rat cerebellar granule neuronal culture | • Inhibiting HDAC3 with IGF-1 or inhibition of GSK3β ameliorate neurotoxicity-induced death of neurons. | • HDAC3 and GSK3β may be involved in neurotoxicity-induced death of neurons. | Manuscript and colleagues112 |
| Liposaccharide-induced neuroinflammation rat model | • Ischaemic preconditioning such as acetate supplementation helps to induce H3K9, H4K8 and H4K16 acetylation, which reduces neuroglial inflammation and secretion of proinflammatory cytokine IL-1β. | • Ischaemic preconditioning using various methods may be helpful in reducing neuroinflammation and thereby induce a state of tolerance towards stroke. | Garcia-Bonilla and colleagues113  
Soliman and colleagues114 |
| Model used | Outcome during stroke | Lesson learnt from studies | References |
|------------|-----------------------|-----------------------------|------------|
| In vivo mouse model | | | |
| MCAO post-stroke dementia mouse model | Treatment with icariin flavonoid helps to promote histone acetylation, which in turn ameliorates cognitive impairment in PSD post-stroke mice. | Histone acetylation may be important to restore cognition following post-stroke. | Tu and colleagues<sup>119</sup> |
| Knockout mouse model | Loss of HDAC4 resulted in impairment in learning, memory and synaptic plasticity. | HDAC4 is a positive regulator of learning and memory formation. | Kim and Akhtar<sup>21</sup> |
| In vitro neuronal model of stroke | | | |
| Global transient cerebral ischaemia rat model | Inhibition of H3K9 methyltransferase G9a and SUV39H1 using chaetocin and RNA interference displayed neuronal resistance to cell death and upregulation of BDNF. | Histone H3K9 methylation may promote neuronal cell death and decreased synaptic plasticity following stroke. | Schweizer and colleagues<sup>122</sup> |
| ICAO mouse model | Mild to moderate ischaemia resulted in increased expression of H3K9me<sub>2</sub> and demethylation of H3K4, while treatment with DMOG increased H3K9me<sub>2</sub> and improves stroke functional outcome. | Differential histone methylation patterns spatially and temporally following stroke may indicate differential regulation of stroke inflammation and damage. | Chakravarty and colleagues<sup>23</sup> |
| Types of epigenetic modification | Model used | Outcome during stroke | Lesson learnt from studies | References |
|----------------------------------|------------|-----------------------|---------------------------|------------|
| Human and mouse brain            | • TNF-α reduces H3K9 and H3K27 methylation, which upregulates ICAM-1 in cerebral vasculature.  
• Inhibitor and overexpression studies reveal that G9a and KDM4B are implicated. | • G9a and KDM4B concomitant interaction may be important in modulating TNF-α influence on H3K9 and H3K27 methylation levels, which may further determine the expression of ICAM-1 and neutrophil migration. | Choi and colleagues\(^\text{124}\) |
| Human stroke patients            | • Serum TNF-α is correlated with H3K9Ac and H3K4me\(_2\). | • TNF-α levels may influence H3K9Ac and H3K4me\(_2\) levels and thereby influence stroke outcome. | Gómez-Uriz and colleagues\(^\text{125}\) |
| Astrocyte and neuronal cell culture | • HDAC inhibition increase H3K4me\(_2\) at Hsp70 promoter region. | • H3K4me\(_2\) may upregulate neuroprotective protein expression. | Marinova and colleagues\(^\text{124}\) |
| Diet-induced hyperhomocysteinemia rat model | • Lower levels of ADMA reported in hyperhomocysteinemia rat model. | • A causal link between hyperhomocysteinemia and histone arginine methylation may exist. | Esse and colleagues\(^\text{53}\) |
| In vitro and in vivo model       | • Levels of ADMA and SDMA are highly expressed following stroke, which inhibit NOS and affect atherosclerosis and impair endothelial function. | • ADMA may contribute to reduction in cerebral blood flow, oxidative stress and excitotoxicity-mediated neuronal death during stroke. | Chen and colleagues\(^\text{52}\) |
| Human stroke patients            | • ADMA and SDMA levels are associated with expression of inflammatory mediators following ischaemic stroke, such as MCP-1, MMP-9, TIMP-1, IL-6, C-reactive protein and S100B, which coincide with histone arginine methylation. | • Increasing histone arginine methylation may upregulate proinflammatory mediators during ischaemic stroke. | Chen and colleagues\(^\text{127}\) |
| MicroRNAs                        | Focal cerebral ischaemia rat model  
• mIR-124a is reduced in neural progenitor cells in the subventricular zone of the brain with the concomitant increase in Notch signalling.  
• Also involved in stroke-induced neurogenesis.  
• mIR-124 is upregulated in plasma of stroke rats. | • mIR-124a may play a protective role during stroke via neurogenesis.  
• mIR-124a expression during stroke follows a differential spatial pattern. Function differences during stroke need to be considered. | Chen and colleagues\(^\text{127}\)  
Liu and colleagues\(^\text{129}\)  
Laterza and colleagues\(^\text{130}\) |
| Human stroke patients            | • mIR-30a and mIR-126 levels in the blood are reduced until 24 weeks later. | • Both mIR-3a and mIR-126 may be involved during stroke and follow a temporal pattern of expression.  
• Functional studies need to be conducted. | Long and colleagues\(^\text{131}\) |
| Types of epigenetic modification | Model used | Outcome during stroke | Lesson learnt from studies | References |
|---------------------------------|------------|-----------------------|---------------------------|------------|
| Human stroke patients           | • Let-7b is lower in large-artery stroke patients than non-stroke patients.  
• Let-7b is higher in ischaemic stroke patients than healthy individuals. | • Let-7b may play a differential role in large-artery and ischaemic stroke.  
• Differential expression level of Let-7b across different stroke subtypes may suggest differential contribution of Let-7b in the pathogenesis of stroke subtypes. | Long and colleagues\(^{131}\) |
| Human stroke patients           | • miR-19a is reduced following ischaemic stroke, is associated with TFPI, SERPIN1 and tissue factor III to modulate thrombus formation. | • miR-19a may contribute to thrombus formation, an early event in stroke. | Jickling and colleagues\(^ {132}\) |
| Human stroke patients           | • miR-let-7i, miR-122 and miR-148 are downregulated during ischaemic stroke and associated with various clotting mediators. | • miR-let-7i, miR-122 and miR-148 may regulate clotting, an early event in stroke. | Jickling and colleagues\(^ {132}\) |
| In vitro and in vivo model      | • miR-155 regulates macrophage differentiation and adoption of a proinflammatory response.  
• It also regulates proinflammatory signalling in microglia, via the downregulation of SOCS-1, thereby promoting inflammation via upregulation of iNOS.  
• Inhibition of miR-155 via antisense oligonucleotide reduces inflammation in microglia and inflammation-induced neuronal apoptosis.  
• miR-155 promotes both TNF and IL-1β secretion via signalling of NF-κB and TLR-4, and downregulation of MyD88.  
• Administration of miR-155 antagomir acetylbritannilactone decreases cerebral infarct volume via reduced expression of proinflammatory molecules, resulting in neurological improvement during stroke. | • miR-155 is involved in regulating inflammatory responses in microglia.  
• miR-155 is involved in regulating inflammatory processes during stroke. | Jablonski and colleagues\(^ {133}\), Cardoso and colleagues\(^ {134}\), O’Connell and colleagues\(^ {135}\), Guedes and colleagues\(^ {136}\) |
| MCAO mouse model                | • Administration of miR-210 inhibitor decreases expression of proinflammatory molecules such as TNF-α, IL-1β and IL-6, and chemokines CCL2 and CCL3.  
• Overall, inhibition of miR-210 reduces cerebral infarct volume and attenuates neurological impairment. | • miR-210 is involved in proinflammatory processes during stroke. | Huang and colleagues\(^ {137}\) |
| In vitro and in vivo model      | • miR-223 suppresses NLRP3 inflammasome by binding to its 3’ UTR sites following intracerebral haemorrhage, thereby reducing IL-1β and caspase-1 processing.  
• Overall, this reduces brain oedema and improves neurological score following stroke. | • miR-210 is involved in anti-inflammatory processes during stroke via targeting of NLRP3 inflammasome. | Fann and colleagues\(^ {10}\), Yang and colleagues\(^ {16}\), Yang and colleagues\(^ {138}\) |
| Types of epigenetic modification | Model used | Outcome during stroke | Lesson learnt from studies | References |
|---------------------------------|------------|-----------------------|-----------------------------|------------|
| Murine BV2 microglial cell culture | • miR-let-7a mediates the upregulation of anti-inflammatory IL-4, IL-10 and recovery-promoting mediators BDNF in microglia.  
• miR-let-7a mediates the downregulation of proinflammatory iNOS and IL-6. | • miR-let-7a is involved in anti-inflammatory and recovery processes during stroke. | Cho and colleagues\(^{139}\) |
| Distal MCAO mouse model | • miR-155 upregulates expression of anti-inflammatory IL-10. | • miR-155 is involved in anti-inflammatory processes during stroke. | Caballero-Garrido and colleagues\(^{140}\) |
| In vitro and in vivo model | • miR-146 prevents endothelial cell activation via suppression of NF-κB, MAPK and EGR transcriptional activity. | • miR-146 is involved in anti-inflammatory processes during stroke. | Cheng and colleagues\(^{143}\) |
| Human endothelial cell culture | • miR-31 and miR-17-3P are both induced by TNF and help to inhibit expression of E-selectin and ICAM-1.  
• Inhibition of these miRNAs resulted in increased neutrophil adhesion to endothelial cells. Administration of miRNA mimetics prevented neutrophil-endothelial cell interactions. | • miR-31 and miR-17-3P are involved in anti-inflammatory processes during stroke. | Suárez and colleagues\(^{144}\) |
| Human stroke patients MCAO rat model | • miR-126 inhibits VCAM-1 expression. | • miR-126 is involved in anti-inflammatory processes during stroke. | Sepramaniam and colleagues\(^{145}\) |
| Human subjects | • Single nucleotide polymorphism of miR-491-5p in Chinese population increases the risk of cerebral ischaemia via alteration in binding site interaction. miR-491-5p inhibits expression of MMP-9, and the presence of this polymorphism upregulates MMP-9 expression, and promotion of blood–brain barrier disruption and leukocyte extravasation. | • miR-491-5p is involved in anti-inflammatory processes during stroke. | Yuan and colleagues\(^{146}\) |
| Human stroke patients | • Functional polymorphism of 3′ UTR site of angioptienin-1 gene altered binding site for miR-211, which reduces stroke occurrence. Angioptienin-1 is a factor involved in strengthening of vasculature. | • miR-211 is involved in vasculature strengthening, which may be protective against stroke occurrence. | Chen and colleagues\(^{147}\) |
| Permanent MCAO rat model | • miR-107 target Dicer-1, helps to upregulate expression of VEGF, which facilitates post-stroke angiogenesis. | • miR-107 may be involved in post-stroke angiogenesis, and may facilitate stroke recovery. | Li and colleagues\(^{148}\) |
interplay of multiple genes and environmental factors. This may partly explain why findings from animal models may not be translatable to human subjects as their epigenomes will differ greatly. As such, this review proposes the exploration of an epigenetic approach to intervention for stroke, involving not only epigenetic-related drugs, but also positive lifestyle practices such as dietary restriction and healthy eating.

**Funding**
This work was supported by the National University of Singapore strategic grant (Memory Network Program: R-185-000-271-646), National Medical Research Council Research Grants (NMRC-CBRG-0102/2016), Singapore National Medical Research Council Research Grants (NMRC/OFIRG/0036/2017) and the National Health and Medical Research Council of Australia (APP1079467; APP1064686; APP1085323).

**Conflict of interest statement**
The authors declare that there is no conflict of interest.

**ORCID iD**
Thiruma V. Arumugam https://orcid.org/0000-0002-3377-0939

**References**
1. Deb P, Sharma S and Hassan KM. Pathophysiologic mechanisms of acute ischemic stroke: an overview with emphasis on therapeutic significance beyond thrombolysis. *Pathophysiology* 2010; 17: 197–218.
2. Zhan X, Tian Y, Liu D, et al. Signatures of cardioembolic and large vessel ischemic stroke. *Ann Neuro* 2011; 68(5): 681–692.
3. Yew KS and Cheng EM. Diagnosis of acute stroke. *Am Fam Physician* 2015; 91: 528–536.
4. Anrather J and Iadecola C. Inflammation and stroke: an overview. *Neurotherapeutics* 2016; 13: 661–670.
5. Allen CL and Bayraktutan U. Risk factors for ischaemic stroke. *Int J Stroke* 2008; 3: 105–116.
6. Zavoreo I, Bašić-Kes V and Demarin V. Triple H (hypertension, hyperlipidemia, hyperglycemia) and stroke. *Period Biol* 2012; 114: 269–275.
7. Mergenthaler P, Dirschl U and Meisel A. Pathophysiology of stroke: lessons from animal models. *Metab Brain Dis* 2004; 19: 151–167.
8. Markus H. The pathophysiology of stroke. *Br J Cardiol* 2001; 586–589.
9. Grotta JC and Helgason C. Ischemic stroke pathophysiology. *J Stroke Cerebrovasc Dis* 1999; 8: 114–116.
10. Fann DYW, Lee SY, Manzanero S, et al. Pathogenesis of acute stroke and the role of inflammasomes. *Aging Res Rev* 2013; 12: 941–966.
11. Ouyang YB. Inflammation and stroke. *Neurosci Lett* 2013; 548: 1–3.
12. Ceulemans AG, Zgavc T, Kooijman R, et al. The dual role of the neuroinflammatory response after ischemic stroke: modulatory effects of hypothermia. *J Neuroinflammation* 2010; 7: 1–18.
13. Woodruff TM, Thundyil J, Tang SC, et al. Pathophysiology, treatment, and animal and cellular models of human ischemic stroke. *Mol Neurodegener* 2011; 6: 11.
14. Huang J, Upadhyay UM and Tamargo RJ. Inflammation in stroke and focal cerebral ischemia. *Surg Neurol* 2006; 66: 232–245.
15. Zoppo G, Ginis I, Hallenbeck JM, et al. Inflammation and stroke: putative role for cytokines, adhesion molecules and iNOS in brain response to ischemia. *Brain Pathol* 2006; 10: 95–112.
16. Yang-Wei Fann D, Lee SY, et al. Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke. *Cell Death Dis* 2013; 4: 1–10.
17. Franchi L, Eigenbrod T, Muñoz-Planillo R, et al. The inflammasome: a caspase-1 activation platform regulating immune responses and disease pathogenesis. *Nat Immun* 2009; 10: 241.
18. Dziedzic T. Systemic inflammation as a therapeutic target in acute ischemic stroke. *Expert Rev Neurother* 2015; 15: 523–531.
19. Jamrozik K, Broadhurst RJ, Anderson CS, et al. The role of lifestyle factors in the etiology of stroke: a population-based case-control study in Perth, Western Australia. *Stroke* 1994; 25: 51–59.
20. Zhang Y, Tuomilehto J, Jousilahti P, et al. Lifestyle factors on the risks of ischemic and hemorrhagic stroke. *Arch Intern Med* 2011; 171: 1811–1818.
21. Hwang JY, Aromolaran KA and Zukin RS. Epigenetic mechanisms in stroke and epilepsy. *Neuropsychopharmacology* 2013; 38: 167–182.
22. Huypens P, Sass S, Wu M, et al. Epigenetic germline inheritance of diet-induced obesity and insulin resistance. *Nat Genet* 2016; 48: 14–17.

23. Qureshi IA and Mehler MF. Emerging role of epigenetics in stroke. *Arch Neurol* 2010; 67: 1316–1322.

24. Portela A and Esteller M. Epigenetic modifications and human disease. *Nat Biotechnol* 2010; 28: 1057–1068.

25. Boyanapalli SSS and Kong ANT. ‘Curcumin, the king of spices’: epigenetic regulatory mechanisms in the prevention of cancer, neurological, and inflammatory diseases. *Curr Pharmcol Rep* 2015; 1: 129–139.

26. Zhang Y and Reinberg D. Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. *Genes Dev* 2001; 15: 2343–2360.

27. Bécavin C, Barbi M, Victor JM, et al. Transcription within condensed chromatin: steric hindrance facilitates elongation. *Biophys J* 2010; 98: 824–833.

28. Panawala L, Between D, View E, et al. Difference between euchromatin and heterochromatin: basic mechanisms and role in cardiovascular disease. *Circulation* 2011; 123: 2145–2156.

29. Qureshi IA and Mehler MF. Emerging role of epigenetics in stroke: part 1. DNA methylation and chromatin modifications. *Arch Neurol* 2010; 67: 1316–1322.

30. Moore LD, Le T and Fan G. DNA methylation and its basic function. *Neuropsychopharmacology* 2013; 38: 23–38.

31. Feng J, Zhou Y, Campbell SL, et al. Dnmt1 and Dnmt3a maintain DNA methylation and regulate synaptic function in adult forebrain neurons. *Nat Neurosci* 2010; 13: 423–430.

32. Kim KC, Friso S and Choi SW. DNA methylation, an epigenetic mechanism connecting folate to healthy embryonic development and aging. *J Nutr Biochem* 2009; 20: 917–926.

33. Alluri RV, Mohan V, Komandur S, et al. MTHFR C677T gene mutation as a risk factor for arterial stroke: a hospital based study. *Eur J Neurol* 2005; 12: 40–44.

34. Daniels LR, Gladman JR, Altaf N, et al. Heterogeneity of association between MTHFR and stroke among European regions: additional population studies are needed in Italy. *Stroke* 2007; 50: 761.

35. Zhou BS, Bu GY, Li M, et al. Tagging SNPs in the MTHFR gene and risk of ischemic stroke in a Chinese population. *Int J Mol Sci* 2014; 15: 8931–8940.

36. Xu GL and Wong J. Oxidative DNA demethylation mediated by Tet enzymes. *Nat Sci Rev* 2015; 2: 318–328.

37. Cooper DN, Mort M, Stenson PD, et al. Methylation-mediated deamination of 5-methylcytosine appears to give rise to mutations causing human inherited disease in CpNpG trinucleotides, as well as in CpG dinucleotides. *Hum Genomics* 2010; 4: 406.

38. Cedar H and Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. *Nat Genet* 2009; 10: 295–304.

39. Qureshi IMM. The emerging role of epigenetics in stroke. *Neurol Rev* 2011; 68: 294–302.

40. Handy D, Castro R and Loscalzo J. Epigenetic modifications basic mechanisms and role in cardiovascular disease. *Circulation* 2011; 123: 2145–2156.

41. Legube G and Trouche D. Regulating histone acetyltransferases and deacetylases. *EMBO Rep* 2003; 4: 944–947.

42. Fry CJ and Peterson CL. Chromatin remodelling enzymes: who’s on first? *Curr Biol* 2001; 11: 185–197.

43. Eberharter A and Becker PB. Histone acetylation: a switch between repressive and permissive chromatin. Second in review on chromatin dynamics. *EMBO Rep* 2002; 3: 224–229.

44. Eberharter A. ATP-dependent nucleosome remodelling: factors and functions. *J Cell Sci* 2004; 117: 3707–3711.

45. Chuang DM, Leng Y, Marinova Z, et al. Multiple roles of HDAC inhibitors in neurodegenerative conditions. *Trends Neurosci.* 2009; 32: 591–601.

46. Gong F and Miller KM. Mammalian DNA repair: HATs and HDACs make their mark through histone acetylation. *Mutat Res Fundam Mol Mech Mutagen* 2013; 750: 23–30.

47. Zhao Y, Lu J, Sun H, et al. Histone acetylation regulates both transcription initiation and elongation of hsp22 gene in Drosophila. *Biochem Biophys Res Commun* 2005; 326: 811–816.

48. Church MC and Fleming AB. A role for histone acetylation in regulating transcription elongation. *Transcription* 2017; 1264: 1–8.

49. Tamburini B and Tyler JK. Localized histone acetylation and deacetylation triggered by
the homologous recombination pathway of double-strand DNA repair. *Mol Cell Biol* 2005; 25: 4903–4913.

50. Chakravarty S, Jhelum P, Bhat UA, *et al*. Insights into the epigenetic mechanisms involving histone lysine methylation and demethylation in ischemia induced damage and repair has therapeutic implication. *Biochim Biophys Acta Mol Basis Dis* 2017; 1863: 152–164.

51. Lan F and Shi Y. Epigenetic regulation: methylation of histone and non-histone proteins. *Sci China, Ser C Life Sci* 2009; 52: 311–322.

52. Chen S, Li N, Deb-Chatterji M, *et al*. Asymmetric dimethyarginine as marker and mediator in ischemic stroke. *Int J Mol Sci* 2012; 13: 15983–16004.

53. Esse R, Florindo C, Imbard A, *et al*. Global protein and histone arginine methylation are affected in a tissue-specific manner in a rat model of diet-induced hyperhomocysteinemia. *Biochim Biophys Acta Mol Basis Dis* 2013; 1832: 1708–1714.

54. Chisholm NC, Henderson ML, Selvamani A, *et al*. Histone methylation patterns in astrocytes are influenced by age following ischemia. *Epigenetics* 2015; 10: 142–152.

55. Han J, Lee Y, Yeom K, *et al*. The Drosha–DGCR8 complex in primary microRNA processing. *Genes Dev* 2004; 18: 3016–3027.

56. Yi R, Qin Y, Macara IG, *et al*. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. *Genes Dev* 2003; 17: 3011–3016.

57. Koscianska E, Starega-Roslan J and Krzyzosiak WJ. The role of dicer protein partners in the processing of microRNA precursors. *PLoS One* 2011; 6:e28548.

58. Udali S, Guarini P, Moruzzi S, *et al*. Cardiovascular epigenetics: from DNA methylation to microRNAs. *Mol Aspects Med* 2013; 34: 883–901.

59. Vidigal JA and Ventura A. The biological functions of miRNAs: lessons from in vivo studies. *Trends Cell Biol* 2015; 25: 137–147.

60. Khoshnam SE, Winlow W and Farzaneh M. The interplay of microRNAs in the inflammatory mechanisms following ischemic stroke. *J Neuropathol Exp Neurol* 2017; 76: 548–561.

61. Meller R, Pearson A and Simon RP. Dynamic changes in DNA methylation in ischemic tolerance. *Front Neurol* 2015; 6: 1–10.

62. Baccarelli A, Wright R, Bollati V, *et al*. Ischemic heart disease and stroke in relation to blood DNA methylation. *Epidemiology* 2010; 21: 819–828.

63. Baccarelli A, Tarantini L, Wright RO, *et al*. Repetitive element DNA methylation and circulating endothelial and inflammation markers in the VA normative aging study. *Epigenetics* 2010; 5: 222–228.

64. Gallego-Fabrega C, Carrera C, Reny J-L, *et al*. TRAF3 epigenetic regulation is associated with vascular recurrence in patients with ischemic stroke. *Stroke* 2016; 47: 1180–1186.

65. Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. *J Cell Mol Med* 2002; 6: 1–12.

66. Lawler PR and Lawler J. Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2. *Cold Spring Harb Perspect Med* 2012; 2: 1–13.

67. Gutierrez LS, Lopez-Dee Z and Pidcock K. Thrombospondin-1: multiple paths to inflammation. *Mediators Inflamm.* 2011; 2011. Article ID 296069.

68. Res C. Thrombospondin-1: Multiple Paths to Inflammation. HHS public access. 2016; 117: 129–141.

69. Gallego-Fabrega C, Carrera C, Reny JL, Fontana P, *et al*. PPM1A methylation is associated with vascular recurrence in aspirin-treated patients. *Stroke* 2016; 47: 1926–1929.

70. Soriano-Tárraga C, Jiménez-Conde J, Giralt-Steinhauer E, *et al*. Global DNA methylation of ischemic stroke subtypes. *PLoS One* 2014; 9: e96543.

71. Soriano-Tárraga C, Giralt-Steinhauer E, Mola-Caminal M, *et al*. Ischemic stroke patients are biologically older than their chronological age. *Aging (Albany NY)* 2016; 8: 2655–2666.

72. Chestnut BA, Chang Q, Price A, *et al*. Epigenetic regulation of motor neuron cell death through DNA methylation. *J Neurosci* 2011; 31: 16619–16636.

73. Feng J, Zhou Y, Campbell SL, *et al*. Methylation and synaptic function in adult forebrain neurons. *Nat Neurosci* 2011; 13: 423–430.

74. Yu J, Qiu Y, Yang J, *et al*. DNMT1–PPARγ pathway in macrophages regulates chronic inflammation and atherosclerosis development in mice. *Sci Rep* 2016; 6: 1–11.

75. Del Pilar Valencia-Morales M, Zaina S, Heyn H, *et al*. The DNA methylation drift of the
atherosclerotic aorta increases with lesion progression. *BMC Med Genomics* 2015; 8: 1–9.

76. Endres M, Meisel A, Biniszkwicz D, et al. DNA methyltransferase contributes to delayed ischemic brain injury. *J Neurosci* 2000; 20: 3175–3181.

77. Barr TL, VanGilder RL, Seiberg R, et al. Systemic transcriptional alterations of innate and adaptive immune signaling pathways in atherosclerosis, ischemia stroke, and myocardial infarction. *J Bioanal Biomed* 2016; 7(2): 29–34.

78. Chamorro Á, Urra X and Planas AM. Infection after acute ischemic stroke: a manifestation of brain-induced immunodepression. *Stroke* 2007; 38: 1097–1103.

79. Zhang Z, Yan Q, Guo J, et al. A plasma proteomics method reveals links between ischemic stroke and MTHFR C677T genotype. *Sci Rep* 2017; 7: 1–10.

80. Kanth VVR, Golla JP, Sastry BKS, et al. Genetic interactions between MTHFR (C677T), methionine synthase (A2756G, C2758G) variants with vitamin B12 and folic acid determine susceptibility to premature coronary artery disease in Indian population. *J Cardiovasc Dis Res* 2011; 2: 156–163.

81. Botto Lorenzo D and Yang Q. Folic acid receptors. *Am J Epidemiol* 2000; 151:862–877.

82. Trabetti E. Homocysteine, MTHFR gene polymorphisms, and cardio-cerebrovascular risk. *J Appl Genet* 2008; 49: 267–282.

83. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke. *Am Med Assoc* 2015; 288: 2015–2023.

84. Gao S, Wang L, Liu W, et al. The synergistic effect of homocysteine and lipopolysaccharide on the differentiation and conversion of raw264.7 macrophages. *J Inflamm* 2014; 11: 1–6.

85. Faraci FM and Lentz SR. Hyperhomocysteinemia, oxidative stress, and cerebral vascular dysfunction. *Stroke* 2004; 35: 345–347.

86. Cronin S, Furie KL and Kelly PJ. Dose-related association of MTHFR 677T allele with risk of ischemic stroke: evidence from a cumulative meta-analysis. *Stroke* 2005; 36: 1581–1587.

87. Goldstein LB. Novel risk factors for stroke: homocysteine, inflammation, and infection. *Curr Atheroscler Rep* 2000; 2: 110–114.

88. Ucar F, Sönmez M, Ovali E, et al. MTHFR C677T polymorphism and its relation to ischemic stroke in the Black Sea Turkish population. *Am J Hematol* 2004; 76: 40–43.

89. Somarajan BI, Kalita J, Mittal B, et al. Evaluation of MTHFR C677T polymorphism in ischemic and hemorrhagic stroke patients: a case-control study in a Northern Indian population. *J Neurol Sci* 2011; 304: 67–70.

90. Younes-Mhenni S, Derex L, Berruyer M, et al. Large-artery stroke in a young patient with Crohn’s disease: role of vitamin B6 deficiency-induced hyperhomocysteinemia. *J Neurol Sci* 2004; 221: 113–115.

91. Sánchez-Moreno C, Jiménez-Escrig A and Martin A. Stroke: roles of B vitamins, homocysteine and antioxidants. *Nutr Res Rev* 2009; 22: 49–67.

92. Pezzini A, Grassi M, Del Zotto E, et al. Migraine mediates the influence of C677T MTHFR genotypes on ischemic stroke risk with a stroke-subtype effect. *Stroke* 2007; 38: 3145–3151.

93. Kelly PJ, Kistler JP, Shih VE, et al. Inflammation, homocysteine, and vitamin B6 status after ischemic stroke. *Stroke* 2004; 35: 12–15.

94. Saposnik G. The role of vitamin B in stroke prevention: a journey from observational studies to clinical trials and critique of the VITATOPS. *Stroke* 2011; 42: 838–842.

95. Zhao M, Wu G, Li Y, et al. Meta-analysis of folic acid efficacy trials in stroke prevention insight into effect modifiers. *Neurology* 2017; 88: 19.

96. Keat Wei L, Sutherland H, Au A, et al. A potential epigenetic marker mediating serum folate and vitamin B12 levels contributes to the risk of ischemic stroke. *Biomed Res Int* 2015; 2015: 1–4.

97. Suuronen T, Huuskonen J, Pihlaja R, et al. Regulation of microglial inflammatory response by histone deacetylase inhibitors. *J Neurochem* 2003; 87: 407–416.

98. Patnala R, Arumugam TV, Gupta N, et al. HDAC inhibitor sodium butyrate-mediated epigenetic regulation enhances neuroprotective function of microglia during ischemic stroke. *Mol Neurobiol* 2017; 54: 6391–6411.

99. Patnala R, Arumugam T and Dheen ST. Histone modification in activated microglia during ischemic stroke. *Front Cell Neurosci* 2016.
100. Yildirim F, Gertz K, Kronenberg G, et al. Inhibition of histone deacetylation protects wildtype but not gelsolin-deficient mice from ischemic brain injury. Exp Neurol 2008; 210: 531–542.

101. Sinn DI, Kim SJ, Chu K, et al. Valproic acid-mediated neuroprotection in intracerebral hemorrhage via histone deacetylase inhibition and transcriptional activation. Neurobiol Dis 2007; 26: 464–472.

102. Wang Z, Leng Y, Tsai L-K, et al. Valproic acid attenuates blood–brain barrier disruption in a rat model of transient focal cerebral ischemia: the roles of HDAC and MMP-9 inhibition. J Cereb Blood Flow Metab 2011; 31: 52–57.

103. Park MJ and Sohrabji F. The histone deacetylase inhibitor, sodium butyrate, exhibits neuroprotective effects for ischemic stroke in middle-aged female rats. J Neuroinflammation 2016; 13: 1–14.

104. Kim HJ, Rowe M, Ren M, et al. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J Pharmacol Exp Ther 2007; 321: 892–901.

105. Faraco G, Pancani T, Formentini L, et al. Pharmacological inhibition of histone deacetylases (HDACs) by suberoylanilide hydroxamic acid (SAHA) specifically alters gene expression and reduces ischemic injury in the mouse brain. Mol Pharmacol 2006; 70: 1876–1884.

106. Langley B, Brochier C and Rivieccio MA. Targeting histone deacetylases as a multifaceted approach to treat the diverse outcomes of stroke. Stroke 2009; 40: 2899–2905.

107. Jhelum P, Maitra S, Shailaja K, et al. Role of histone based epigenetic modifications in cerebral ischemia induced striatal damage in internal carotid artery occlusion (ICAO) rodent models. Conference: Conference: International Conference on New Dimentions in Chemistry and Chemical Technologies. 1: 1–12.

108. Correa F, Mallard C, Nilsson M, et al. Activated microglia decrease histone acetylation and Nrf2-inducible anti-oxidant defence in astrocytes: restoring effects of inhibitors of HDACs, p38 MAPK and GSK3β. Neurobiol Dis 2011; 44: 142–151.

109. Tang Y, Lin YH, Ni HY, et al. Inhibiting histone deacetylase 2 (HDAC2) promotes functional recovery from stroke. J Am Heart Assoc 2017; 6: pii: e007236.

110. Matsuoka H, Fujimura T, Hayashi M, et al. Disruption of HDAC4/N-CoR complex by histone deacetylase inhibitors leads to inhibition of IL-2 gene expression. Biochem Pharmacol 2007; 74: 465–476.

111. Georgopoulos K. From immunity to tolerance through HDAC. Nat Immunol 2009; 10: 13–14.

112. Bardai FH and D’Mello SR. Selective toxicity by HDAC3 in neurons: Regulation by Akt and GSK3β. J Neurosci 2011; 31 (5): 1746–1751.

113. Garcia-Bonilla L, Benakis C, Moore J, et al. Immune mechanisms in cerebral ischemic tolerance. Front Neurosci 2014; 8: 1–19.

114. Soliman ML, Smith MD, Houdek HM, et al. Acetate supplementation modulates brain histone acetylation and decreases interleukin-1β expression in a rat model of neuroinflammation. J Neuroinflammation 2012; 9: 1–14.

115. Dinagl U, Becker K and Meisel A. Preconditioning and tolerance against cerebral ischemia: from experimental strategies to clinical use. Lancet Neurol 2009; 8: 398–412.

116. Nair RD and Lincoln NB. Cognitive rehabilitation for memory deficits following stroke. Cochrane Database Syst Rev 2007; 3: CD002293.

117. Guan JS, Haggarty SJ, Giacometti E, et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 2009; 459: 55–60.

118. Vecsey CG, Hawk JD, Lattal KM, et al. NIH public access. J Neurosci 2010; 27: 6128–6140.

119. Tu F, Pang Q, Huang T, et al. Apigenin ameliorates post-stroke cognitive deficits in rats through histone acetylation-mediated neurochemical alterations. Med Sci Monit 2017; 23: 4004–4013.

120. Wang X, Li J, Qian L, et al. Icariin promotes histone acetylation and attenuates post-stroke cognitive impairment in the central cholinergic circuits of mice. Neuroscience 2013; 236: 281–288.

121. Kim M and Akhtar M. An essential role for histone deacetylase 4 in synaptic plasticity and memory formation. J Neurosci 2012; 32: 10879–10886.

122. Schweizer S, Harms C, Lerch H, et al. Inhibition of histone methyltransferases SUV39H1 and G9a leads to neuroprotection in an in vitro model of cerebral ischemia. J Cereb Blood Flow Metab 2015; 35: 1640–1647.

123. Zhang YZ, Zhang QH, Ye H, et al. Distribution of lysine-specific demethylase 1 in the brain of rat and its response in transient global cerebral ischemia. Neurosci Res 2010; 68: 66–72.
124. Choi JY, Yoon SS, Kim SE, et al. KDM4B histone demethylase and G9a regulate expression of vascular adhesion proteins in cerebral microvessels. *Sci Rep* 2017; 7: 1–15.

125. Gómez-Uriz AM, Goyenechea E, Campión J, et al. Epigenetic patterns of two gene promoters (TNF-α and PON) in stroke considering obesity condition and dietary intake. *J Physiol Biochem* 2014; 70: 603–614.

126. Marinova Z, Leng Y, Leeds P, et al. Histone deacetylase inhibition alters histone methylation associated with heat shock protein 70 promoter modifications in astrocytes and neurons. *Neuropsychopharmacology* 2011; 60: 1109–1115.

127. Chen S, Martens-Lobenhoffer J, Weissenborn K, et al. Association of dimethylarginines and mediators of inflammation after acute ischemic stroke. *J Neuroinflammation* 2012; 9: 1–9.

128. Guo D, Liu J, Wang W, et al. Alteration in abundance and compartmentalization of inflammation-related miRNAs in plasma after intracerebral hemorrhage. *Stroke* 2013; 44: 1739–1742.

129. Liu XS, Chopp M, Zhang RL, et al. MicroRNA profiling in subventricular zone after stroke: MiR-124a regulates proliferation of neural progenitor cells through notch signaling pathway. *PLoS One* 2011; 6: 1–11.

130. Laterza OF, Lim L, Garrett-Engele PW, et al. Plasma microRNAs as sensitive and specific biomarkers of tissue injury. *Clin Chem* 2009; 55: 1977–1983.

131. Long G, Wang F, Li H, et al. Circulating miR-30a, miR-126 and let-7b as biomarker for ischemic stroke in humans. *BMC Neurol* 2013; 13: 1–10.

132. Jickling GC, Ander BP, Zhan X, et al. MicroRNA expression in peripheral blood cells following acute ischemic stroke and their predicted gene targets. *PLoS One* 2014; 9: 1–5.

133. Jablonski KA, Gaudet AD, Amici SA, et al. Control of the inflammatory macrophage transcriptional signature by miR-155. *PLoS One* 2016; 11: 1–21.

134. Cardoso AL, Guedes JR, Pereira de Almeida L, et al. miR-155 modulates microglia-mediated immune response by down-regulating SOCS-1 and promoting cytokine and nitric oxide production. *Immunology*. 2012; 135: 73–88.

135. O’Connell RM, Taganov KD, Boldin MP, et al. MicroRNA-155 is induced during the macrophage inflammatory response. *Proc Natl Acad Sci* 2007; 104: 1604–1609.

136. Guedes J, Cardoso ALC and Pedroso De Lima MC. Involvement of microRNA in microgliamediated immune response. *Clin Dev Immunol*. 2013; 2013: 1–11.

137. Huang L, Ma Q, Li Y, et al. Inhibition of microRNA-210 suppresses pro-inflammatory response and reduces acute brain injury of ischemic stroke in mice. *Exp Neurol* 2018; 300: 41–50.

138. Yang Z, Zhong L, Xian R, et al. MicroRNA-223 regulates inflammation and brain injury via feedback to NLRP3 inflammasome after intracerebral hemorrhage. *Mol Immunol* 2015; 65: 267–276.

139. Cho KJ, Song J, Oh Y, et al. MicroRNA-Let-7a regulates the function of microglia in inflammation. *Mol Cell Neurosci* 2015; 68: 167–176.

140. Caballero-Garrido E, Pena-Philippides JC, Lordkipanidze T, et al. In vivo inhibition of miR-155 promotes recovery after experimental mouse stroke. *J Neurosci* 2015; 35: 12446–12464.

141. Xu LJ, Ouyang YB, Xiong X, et al. Post-stroke treatment with miR-181 antagonim reduces injury and improves long-term behavioral recovery in mice after focal cerebral ischemia. *Exp Neurol* 2015; 264: 1–7.

142. Zhang L, Chopp M, Liu X, et al. Combination therapy with VELCADE and tissue plasminogen activator is neuroprotective in aged rats after stroke and targets microRNA-146a and the toll-like receptor signaling pathway. *Arterioscler Thromb Vasc Biol* 2012; 32: 1856–1864.

143. Cheng HS, Sivachandran N, Lau A, et al. MicroRNA-146 represses endothelial activation by inhibiting pro-inflammatory pathways. *EMBO Mol Med* 2013; 5: 949–966.

144. Suárez Y, Wang C, Manes TD, et al. TNF-induced miRNAs regulate TNF-induced expression of E-selectin and ICAM-1 on human endothelial cells: feedback control of inflammation. *J Immunol* 2010; 184: 21–25.

145. Sepramaniam S, Tan JR, Tan KS, et al. Inhibition of microRNA-223 mediates the anti-inflammatory effect of VEGF in an intracerebral hemorrhage model. *J Neuroinflammation* 2012; 9: 1–9.

146. Yuan M, Zhan Q, Duan X, et al. A functional polymorphism at miR-491-5p binding site in the 3′-UTR of MMP-9 gene confers increased risk for atherosclerotic cerebral infarction in a Chinese population. *Atherosclerosis* 2013; 226: 447–452.
147. Chen J, Yang T, Yu H, et al. A functional variant in the 3′-UTR of angiopoietin-1 might reduce stroke risk by interfering with the binding efficiency of microRNA 211. *Hum Mol Genet* 2010; 19: 2524–2533.

148. Li Y, Mao L, Gao Y, et al. MicroRNA-107 contributes to post-stroke angiogenesis by targeting Dicer-1. *Sci Rep* 2015; 5: 1–13.

149. Goyal M, Menon BK, Van Zwam WH, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. *Lancet* 2016; 387: 1723–1731.

150. Varilly P and Chandler D. NIH public access. *Neuroscience* 2012; 2: 265–275.

151. Overgaard J and Skinhoj E. A paradoxical cerebral hemodynamic effect of hydralazine. *Stroke* 1975; 6: 402–404.

152. Pratt CM, Francis MJ, Seals AA, et al. Antiarrhythmic and hemodynamic evaluation of indecainide and procainamide in nonsustained ventricular tachycardia. *Am J Cardiol* 1990; 66: 68–74.

153. Kalani A, Kamat PK, Tyagi SC, et al. Synergy of homocysteine, microRNA, and epigenetics: a novel therapeutic approach for stroke. *Mol Neurobiol* 2013; 48: 157–168.

154. Endres M, Fan G, Meisel A, et al. Effects of cerebral ischemia in mice lacking DNA methyltransferase 1 in post-mitotic neurons. *Neuroreport* 2001; 12: 3763–3766.

155. Wang YA, Yu X, Silverman PM, et al. NIH public access. *J Neurochem* 2010; 385: 22–29.

156. George S, Kadam SD, Irving ND, et al. Impact of trichostatin A and sodium valproate treatment on post-stroke neurogenesis and behavioral outcomes in immature mice. *Front Cell Neurosci* 2013; 7: 1–17.

157. Xuan A, Long D, Li J, et al. Neuroprotective effects of valproic acid following transient global ischemia in rats. *Life Sci* 2012; 90: 463–468.

158. Noh K-M, Hwang J-Y, Follenzi A, et al. Repressor element-1 silencing transcription factor (REST)-dependent epigenetic remodeling is critical to ischemia-induced neuronal death. *Proc Natl Acad Sci* 2012; 109: E962–E971.

159. Qi X, Hosoi T, Okuma Y, et al. Sodium 4-phenylbutyrate protects against cerebral ischemic injury. *Mol Pharmacol* 2004; 66: 899–908.

160. Srinivasan K and Sharma SS. Sodium phenylbutyrate ameliorates focal cerebral ischemic/reperfusion injury associated with comorbid type 2 diabetes by reducing endoplasmic reticulum stress and DNA fragmentation. *Behav Brain Res* 2011; 225: 110–116.

161. Ma Q, Zhao H, Tao Z, et al. MicroRNA-181c exacerbates brain injury in acute ischemic stroke. *Aging Dis* 2016; 7: 705.

162. Yang X, Tang X, Sun P, et al. MicroRNA-15a/16-1 antagonim ameliorates ischemic brain injury in experimental stroke. *Stroke* 2017; 48: 1941–1947.

163. Rink C and Khanna S. MicroRNA in ischemic stroke etiology and pathology. *Physiol Genomics* 2011; 43: 521–528.

164. Martinez B, Peplow PV. Immunomodulators and microRNAs as neurorestorative therapy for ischemic stroke. *Neural Regen Res* 2017; 12(6): 865–874.

165. Li Y, Liu Y, Wang Z, et al. MicroRNA: not far from clinical application in ischemic stroke. *ISRN Stroke* 2013; 2013: 1–7.

166. Li WA, Efendizade A and Ding Y. The role of microRNA in neuronal inflammation and survival in the post ischemic brain: a review. *Neurol Res* 2017; 6412: 1–9.

167. Martinez B and Peplow PV. Immunomodulators and microRNAs as neurorestorative therapy for ischemic stroke. *Neural Regen Res* 2017; 12: 865–874.

168. Yan H, Fang M and Liu XY. Role of microRNAs in stroke and poststroke depression. *Sci World J* 2013; 12: 865–874.

169. Fu Y, Zhang N, Ren L, et al. Impact of an immune modulator fingolimod on acute ischemic stroke. *Proc Natl Acad Sci U S A* 2014; 111: 18315–18320.

170. Zhu Z, Fu Y, Tian D, et al. Combination of the immune modulator fingolimod with alteplase in acute ischemic stroke: a pilot trial. *Circulation* 2015; 132: 1104–1112.